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ABSTRACT 
The placenta remains poorly studied despite being implicated in many pregnancy and 
chronic disorders. Trophoblast invasion and nutrient transport are critical placental processes 
where defects can lead to preeclampsia and other diseases. We set out to characterize protein 
pathways underlying those processes, using mouse as a model. We profiled the placenta 
proteome and phosphoproteome at embryonic day (e)7.5, when trophoblast invasion peaks, 
and at e9.5, when nutrient transport is occurring, and integrated this data with RNA-seq. 
Comparing the unmodified proteome and the transcriptome revealed that most 
upregulated proteins are not the result of transcript changes. However, genes upregulated at 
both levels reflected expected functions, such as enrichment of migration processes at e7.5 
and of metabolic processes at e9.5. Proteins that were only upregulated at the protein level 
contained potentially novel genes involved in migration and patterning, and indicated that the 
placenta at e9.5 is under a state of oxidative stress. 
The phosphoproteome revealed novel phosphosites on placental transcription factors 
(TFs) that were conserved in human and differentially phosphorylated in our dataset, 
indicating an important role for the sites in modulating TF function. When we combined the 
phosphoproteome with the other datasets, we found further clues that e9.5 placenta is under a 
state of oxidative stress, and we identified a posttranscriptionally and posttranslationally 
regulated network at this timepoint. 
This analysis provides a systems-level view of gene expression patterns at two critical 
timepoints of placental development, and opens the door for experimental validation of 
potentially novel proteins, phosphosites, and pathways that may be critical for normal 
placental function.
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CHAPTER 1. A REVIEW OF THE LITERATURE 
1.1 General Background 
The placenta, a transient organ that sustains the fetus, has long been shrouded in 
mystery, and many cultures attach spiritual aspects to it. Some cultures believe it to be 
another mother to the child and even dress it after birth (1), while others bury it under fruit-
bearing trees, hoping that it will continue to nourish life (2). 
Indeed, nourishment is a hallmark of placental function, and normal placentation is 
critical for the baby’s growth and survival. It provides oxygen and nutrients, removes wastes, 
protects from infection, and secretes hormones that maintain the pregnancy (3). It is 
imperative that it grows with the fetus and adapts to changes in the uterine environment, 
while also maintaining steady and sufficient blood flow (4). Given all of its roles, it is no 
surprise that the condition of the placenta dictates the outcome of the pregnancy. In addition, 
placental defects can also affect the long-term health of the mother and baby, with 
implications in hypertension, cardiovascular disease, and even some types of cancer (4). 
In this chapter, early mouse and human placentation are described in detail and 
compared. The utility of genome-wide analyses in understanding placental development is 
emphasized, with a focus on proteome and transcriptome profiling. 
1.2 Human Placenta Development 
The development of the placenta starts with the first differentiation event in the 
embryo: formation of the trophectoderm and the inner cell mass. This occurs around 4-5 days 
after fertilization (p.c.), and the embryo at that stage is called a blastocyst (5). The 
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trophoblast cells, derived from the trophectoderm, form the wall of the blastocyst, while the 
inner cell mass, which gives rise to the embryo, is a collection of cells on one side of the 
blastocyst (the embryonic pole). 
Implantation into the uterus follows shortly, around day 6 p.c.: the embryonic pole of 
the blastocyst contacts the endometrium (the epithelial layer of the uterus and its associated 
mucous membrane) (5,6), and trophoblast invasion begins. Cytotrophoblast cells from the 
trophectoderm that contacted the endometrium fuse and become a multinucleated 
syncytiotrophoblast. They continue to expand toward the myometrium (smooth muscle of the 
uterus), displacing uterine cells in their way (5–8). The syncytiotrophoblast also erodes 
maternal tissues and capillaries, embedding the blastocyst deeper into the uterus, until the 
uterine epithelium completely encloses it by day 12 p.c. (5).  
Small cavities, lacunae, appear in the syncytiotrophoblast mass, which continually 
expands to surround the entire blastocyst around 8 days p.c. As maternal vessels are breached 
during trophoblast invasion, these lacunae are filled with maternal blood (5), forming 
maternal sinusoids. The cytotrophoblast cells underlying the syncytiotrophoblast proliferate 
in columns between the lacunae, initiating the formation of chorionic villi (5,9).  
When the umbilical cord, which connects the placenta and the fetus, extends into 
these villi, fetal blood vessels develop, allowing fetal blood to come into proximity with 
maternal blood. The villi branch and expand around maternal sinusoids, a phenomenon 
known as branching morphogenesis, giving rise to the placenta villous tree (5,8,10). This 
highly branched structure maximizes surface area to allow efficient transport between 
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maternal and fetal blood, and it functions in many other aspects of the placenta as well, such 
as hormone secretion, immunity, and metabolic regulation, among others (11,12). 
The cytotrophoblast cells not involved in forming the villi, extravillous 
cytotrophoblast cells (EVTs), continue to migrate into the myometrium and invade and 
remodel uterine spiral arteries. Spiral artery remodeling creates arteries of low resistance and 
strong blood flow, allowing sufficient blood to reach the fetus (5,10,12). This process and its 
importance are detailed in section 1.2.1. 
The definitive structure of the placenta has three main layers. The most proximal to 
the embryo is where physiological exchange between maternal and fetal blood vessels 
occurs. On top of that is the basal plate, composed mainly of trophoblast-lined maternal 
vessels that deliver blood into or out of the fetal placenta. The outer layer of the placenta, the 
placental bed, is comprised of two further layers: the decidua basalis, which is a part of the 
uterus that has undergone a decidual transformation to support fetal growth; and the 
myometrium (13). During decidualization, which occurs every menstrual cycle (14), uterine 
tissue undergoes a transformation characterized by an increase in uterine capillary 
permeability, proliferation and enlargement of the cells, and formation of tight junctions 
between them (8,14). In addition, inflammatory cells get recruited to the site of the reaction 
and produce proinflammatory cytokines (8,14,15). This leads to formation of a new, spongy 
tissue, known as the decidua or deciduum, which can support fetal growth. 
1.2.1 Human trophoblast invasion 
Trophoblast invasion is the process by which EVTs attach the placenta to the uterus 
and remodel maternal uterine vessels to provide sufficient blood flow to the fetus. Invasive 
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EVTs also secrete hormones that maintain the pregnancy, such as human chorionic 
gonadotropin (hCG), and modulate formation of blood and lymph vessels in the decidua (8). 
EVTs originating from the top of the chorionic villi branch out and migrate through 
the placenta to the proximal portion of the myometrium, where they form the placental bed. 
Intriguingly, their journey through these maternal leukocyte-rich tissues does not trigger an 
immune response. The mechanisms involved in this evasion are still under study, as are many 
aspects of trophoblast invasion (12,16).  
There are two main types of EVTs described in current literature: interstitial EVTs 
(iEVTs) that invade the decidua and myometrium, and endovascular EVTs (enEVTs) that 
invade the decidual and uterine spiral arteries. iEVTs start to invade early in pregnancy, and 
complete invasion of the decidua by 8 weeks (17). They then proceed as far as the inner third 
of the myometrium, where invasion is completed by the 22nd week of pregnancy (17). 
Secretion of various proteases, such as matrix metalloproteinases (MMPs), facilitates iEVT 
invasion by degrading the extracellular matrix (ECM) around them (12,18). 
During their journey, iEVTs cluster around the maternal spiral arteries of the decidua 
and the proximal myometrium, aiding the remodeling of spiral arteries by destroying the 
tunica media (smooth muscle cells and elastic material) of the vessels. They then replace it 
with an acellular matrix known as fibrinoid, reducing the elasticity of the arteries and 
releasing them from maternal control (8,12). 
The removal of the tunica media allows enEVTs to complete the remodeling by 
replacing the endothelial cells at the lining of the arteries (10,12,19). During the first 
trimester, enEVTs form trophoblastic plugs that block blood vessels, preventing all blood 
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components but plasma from percolating through. At the beginning of the second trimester, 
these plugs loosen, allowing the establishment of blood flow (20). The structural changes 
caused by spiral artery remodeling result in thin-walled, slack vessels with low resistance to 
blood flow, allowing an undisrupted and sufficient supply to the intervillous spaces. The 
direct contact of the trophoblasts with maternal blood is characteristic of the placentas of 
humans and rodents, among other mammals, and is termed hemochorial placentation 
(16,21,22). 
In addition to rupturing vessels, iEVTs also rupture uterine glands they encounter 
during invasion. These glands are also remodeled and lined by a putative third type of EVTs, 
endoglandular EVTs (23). It is thought that the rupture and remodeling of uterine glands 
serves to release their secretions into the intervillous space as a histiotrophic nutrient source 
before blood flow is established (5,12,24,25). 
The journey of trophoblast invasion outlined so far mirrors cancer metastasis (26), but 
the critical difference is how well-controlled the former is. There are many mechanisms by 
which trophoblast invasion is limited to a healthy extent. iEVTs may play a role in limiting 
their own invasion; there is evidence that, at the placental bed, they fuse to become 
multinucleated cells and release protease inhibitors, which can prevent them from degrading 
the ECM further (8). Other factors that restrict invasion are secreted by cells in the decidua 
(26–29). 
Normal trophoblast invasion is a complex process that contributes to a successful 
pregnancy. Defects in the process are associated with devastating disorders, such as 
preeclampsia (30,31), a leading cause of maternal and fetal mortality (32); IUGR (33), which 
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affects 5-10% of all pregnancies annually (34); placenta accreta (35), whose incidence has 
increased dramatically over the past two decades (36); and gestational trophoblastic disease 
(37). Many of these disorders have severe and long-term consequences on the mother and the 
baby, potentially leading to their death if untreated. In addition, many are only treatable by 
premature delivery, which puts the infant at risk of a host of other complications (38). 
Despite the negative outcomes associated with defective trophoblast invasion, the gene 
networks regulating the process are not well studied, partly because it occurs early in 
pregnancy. Since tissue from normal human placentas are unavailable in large enough 
numbers while trophoblast invasion is occurring, animal models are commonly used to study 
the process in vivo. 
1.2.2 Mouse as a model for human placental development 
Mouse has been used as a model for many aspects of human physiology and disease, 
because of the many biological and genetic similarities shared between mouse and human. 
Mouse has generally been instrumental in furthering our understanding of human placental 
development; mouse mutants that die because of placental defects have shed light on 
important regulatory pathways in human, and suggested many more putative ones (39). In 
addition, given how many essential trophoblast-related signaling pathways are conserved 
between mouse and human in function and expression pattern (41,42), it is very likely that 
the mouse will continue to be invaluable, at least until non-invasive procedures to study the 
early human placenta in vivo are at hand. 
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1.3 Mouse Placenta Development 
As in human, mouse placenta arises from the trophectoderm. Trophectoderm adjacent 
to the inner cell mass (embryonic pole), is termed the polar trophectoderm, while the part of 
it distal to the inner cell mass (abembryonic pole), surrounding the embryonic cavity, is 
termed the mural trophectoderm. Implantation occurs on embryonic day (e)4.5 as cells of the 
mural trophectoderm contact the epithelium on the uterine wall, stimulating the decidual 
reaction (27). 
Cells of the mural trophectoderm differentiate into primary (or mural) trophoblast 
giant cells (TGCs). They are described as “giant” because of their increased cell size, a result 
of accommodating a large DNA content (ploidy level over 500C) (41). TGCs (similar to 
EVTs in human), are characterized by their exceptional invasive and phagocytic capabilities, 
which allow them to effectively displace uterine epithelial cells and implant the embryo into 
the uterine stroma, now a deciduum (42–44). 
After implantation, cells of the polar trophectoderm proliferate and form the 
extraembryonic ectoderm. This continues proliferating, giving rise to a conical protrusion, 
the ectoplacental cone (45). This is apparent by e6 and is the first stage of placental 
development (46). The ectoplacental cone also has trophoblast giant cells at its outer edges, 
and those migrate to the other side of the conceptus (the abembryonic pole), consequently 
surrounding the entire implantation site. These are the secondary (or polar) TGCs; they are 
identical to the primary ones, but are the result of the second wave of terminal differentiation 
during conceptus development. The two types of cells are known as parietal trophoblast giant 
cells (p-TGCs), and are distinguished from other, later types of TGCs by their expression of 
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prolactin 1 (Prl3d1). In contrast to the outer edges, cells on the inside of the ectoplacental 
cone are undifferentiated and highly proliferative. These are trophoblast stem cells (TSCs), 
which give rise to other types of TGCs, described in 1.3.2 (47). At the end of e7, cells from 
the extraembryonic ectoderm, also TSCs, expand to form a thin layer of trophoblast cells 
known as the chorion, the part of the placenta most proximal to the embryo (39). 
As development progresses, the allantois, which arises from the extraembryonic 
mesoderm, contacts the chorion at e8.0-e8.5, initiating labyrinth development (48–51). The 
labyrinth is the site of nutrient, gas, and waste exchange between the mother and the fetus 
(51,52), and is similar to the villous tree in humans. The definitive structure is evident by 
e12.5, but, as in human, the placenta does not stop growing until soon before birth (16,53). 
1.3.1 Mouse trophoblast invasion 
Trophoblast invasion in human and mouse starts with implantation, when trophoblast 
cells erode the extracellular matrix to allow entrance of the blastocyst to the uterus. After the 
embryo is lodged in the deciduum, trophoblast giant cells from the placenta (primarily 
parietal TGCs) continue to invade the uterine epithelium and the blood vessels (54), 
becoming intravascular by e9.5 (55). To provide sufficient blood flow to the growing fetus, 
the TGCs replace endothelial cells in decidual arteries and veins (56), and the blood vessels 
lose resistance (53). Eventually, they are no longer under maternal control and blood flow to 
the placenta increases. 
However, as in human placentation, providing plentiful oxygenated blood is not the 
only purpose of trophoblast invasion. The invasive TGCs are also infiltrating the tissue 
around them, completing the invasion around e18.5 (17). Trophoblast invasion in mouse 
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occurs over two phases. The first is early in pregnancy, coupled to implantation, and 
mediated mainly by the secondary TGCs. The second wave of invasion is later in pregnancy, 
mediated by glycogen cells (discussed in 1.3.2) and starts after e13. It continues until about 
e18.5, shortly before birth (17). 
 While in humans, trophoblast invasion reaches as far as the inner third of the 
myometrium (16,33), invasion in mice is not as extensive, but still occurs throughout the 
deciduum and in all directions, though particularly mesometrially (outwards from the 
placenta) (9,57). 
1.3.2 Subtypes of mouse TGCs 
Trophoblast stem cells differentiate into many cell types, only a subset of which are 
invasive. The differentiated cells perform various unique functions, but common to most is 
an endocrine function- they release hormones, such as placental lactogens and estrogen, to 
maintain the pregnancy, regulate fetal growth and encourage healthy placentation (57,58). 
TSCs can differentiate into the following cell types: p-TGCs, discussed in 1.3, which are the 
main invasive cells in early gestation; channel TGCs (ch-TGCs), which line the channels that 
collect deoxygenated blood from the labyrinth; spiral artery TGCs (spA-TGCs), which 
invade into and line maternal spiral arteries after displacing endothelial cells; canal TGCs (c-
TGCs), which line the canals that deliver maternal blood to the base of the labyrinth; 
sinusoidal TGCs (s-TGCs), which line maternal blood sinusoids in the labyrinth (52); two 
syncytiotrophoblast layers, composed of fused cells, which contribute to the interhemal 
barrier and function in nutrient transport; and spongiotrophoblasts and glycogen cells. The 
last two make up the majority of the junctional zone of the placenta (54), a site of intense 
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endocrine activity (16,53) that also plays a role in the development of the layer beneath it, the 
labyrinth (52,53). The glycogen cells, which appear around e12 (16), are another invasive 
cell type, and mediate the second wave of invasion during mouse pregnancy (17). 
This section has outlined placental development and trophoblast invasion in mouse, 
and highlighted some of its superficial parallels to human placentation. However, mouse and 
human share placental similarities even at the genetic level. Some of the conserved pathways 
are discussed in the next section. 
1.4 Conserved Trophoblast Signaling Pathways 
Many signaling pathways that regulate cell differentiation and invasion are conserved 
between human and mouse. For example, the canonical Wnt pathway is generally important 
for mouse blastocyst implantation, the first step of invasion (59), and Dkk1, an antagonist in 
the pathway, promotes migration and invasion of mouse TGCs (60). Studies on first trimester 
human samples indicate that Wnt signaling also plays a role in migration and invasion of 
EVTs (61,62).  
Notch signaling in mice is also critical for trophoblast invasion; most Notch receptors 
and ligands are expressed throughout the placenta and conditional deletion of Notch2 
resulted in lethality by e11.5 with loss of endovascular invasion (63). In humans, Notch 
receptors and ligands are expressed in the villous and extravillous cytotrophoblasts (64), and 
inhibition of Notch-1 reduced the invasive ability of JEG3 cells (human choriocarcinoma) in 
vitro (65), indicating that Notch signaling may generally be important for trophoblast 
invasion. This is also supported by the observation that preeclamptic and IUGR placentas 
exhibit changes in Notch signaling (66,67). However, more studies are required to validate 
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these findings and to clarify the mechanisms by which this pathway is influencing 
trophoblasts in mouse and in human. 
Another prominent cascade involved in trophoblast invasion is that of transforming 
growth factor beta (TGFβ)/activin. This pathway does not seem to have the same 
conservation as previous ones. While it promotes differentiation of EVTs in first trimester 
explants, it appears to do the opposite in mouse TSC lines, maintaining stemness in the 
presence of Fibroblast Growth Factor 4 (FGF4), and inducing labyrinth-cell differentiation in 
its absence (59). While many similarities exist between mouse and human, so do differences. 
Therefore, findings in mouse should always be confirmed in human. 
1.5 The Central Dogma of Molecular Biology 
Gene expression is the process by which genes encoded in DNA (deoxyribonucleic 
acid) are transcribed into mRNA (messenger ribonucleic acid), and the mRNA is translated 
into protein (68). These three stages, DNA, RNA, and protein, provide ample room for 
regulating gene expression. A gene can be regulated at the DNA level, with epigenetic 
mechanisms, which can dictate how accessible the DNA region is (69); and it can be 
regulated at the transcriptional level, with activators and blockers of transcription, for 
example (70). Once transcribed, the transcript itself can undergo extensive posttranscriptional 
regulation, involving splicing events, non-coding-RNAs, sequestration and other mechanisms 
(71). Beyond that, regulation at the level of translation can also affect gene expression. For 
instance, RNA-binding proteins may disrupt the secondary structure of mRNAs, preventing 
or inducing their translation (72). Finally, posttranslational protein modifications (PTMs), 
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such as phosphorylation and ubiquitination, can destine the protein for degradation, 
activation, or anything in between (73). 
Many fields in biology rely heavily on transcriptomic approaches to study gene 
expression. However, given the considerable regulation that occurs posttranscriptionally, it is 
no surprise that the reliability of mRNA in predicting protein levels has been called to 
question in an ongoing debate (74–78). While this issue has been under discussion for 
decades on a single-gene basis, recent technological advances have allowed it to expand to 
the entire proteome. 
1.5.1 Genome-wide expression analysis approaches 
Assessing global gene expression patterns in a cell or tissue can be approached at the 
level of DNA, RNA, and/or protein. Next generation sequencing makes it relatively simple to 
assess nucleic acids. DNA-sequencing coupled to techniques like Chromatin 
Immunoprecipitation (ChIP) can reveal genome-wide epigenetic modifications that indicate 
active or repressed transcription. RNA-sequencing, or transcriptome profiling, identifies most 
transcripts in a cell or tissue, providing a direct measure of gene expression at the 
transcriptional level. Global protein analyses rely on mass spectrometers to identify and 
quantify proteins and their post-translational modifications. Mass spectrometry for protein 
identification and quantitation remains technologically inferior to nucleic acid sequencing; 
the proteome is rarely characterized in its entirety due to technical limitations, unlike the 
genome and transcriptome. 
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1.5.1.1 High-throughput transcriptomics 
High-throughput techniques to measure RNA include microarrays and RNA-
sequencing (RNA-seq). While microarrays offer the advantage of being inexpensive, their 
low dynamic range makes sequencing much more appealing.  
Microarrays were first used in 1995 (79) to measure RNA expression and quickly 
became the tool of choice for transcriptome profiling. RNA is extracted from the sample, 
converted to complimentary DNA (cDNA), then labelled with fluorescent probes and 
hybridized to complementary oligonucleotide probes on the microarray chip. The 
hybridization efficiency, reflected by fluorescence intensity, is a quantitative measure of 
transcript abundance (80). 
Microarrays are an inexpensive and fast way to profile the transcriptome, but the 
advent of next generation sequencing has mostly replaced them with RNA-seq, which is 
more sensitive, and thereby able to identify and quantify most transcripts in a sample. In 
addition, unlike microarrays, which require predesigned probes for specific genes, RNA-seq 
does not limit detection to already known genes, and therefore allows identification of new 
transcripts. With appropriate sequence assembly, RNA-seq can provide full-length 
sequences, which is not often possible with proteomics, because many peptides are 
undetectable with mass spectrometric technologies (81). 
1.5.1.2 High-throughput proteomics 
The dominant proteome analysis technique is currently liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS). Tandem mass spectrometry ionizes 
proteins or peptides (typically peptides in shotgun proteomics (also known as discovery or 
bottom-up proteomics)), then fragments them further. The measured mass-to-charge ratios of 
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the fragmented ions (m/z) indicate the identity of amino acids corresponding to each parent 
peptide, resulting in mass spectra that can be compared to in silico-generated spectra of 
known proteins, thereby revealing their identity. Quantitatively, the intensity of an m/z peak 
is correlated with the amount of protein from which it was generated. 
In shotgun proteomics, high performance liquid chromatography (typically reverse-
phase) is used prior to the MS step to fractionate the peptides; each peptide passes through 
the LC column at a different speed, based on hydrophobicity, and the eluted peptides then get 
ionized and enter the MS for further fragmentation and measurement. The depth of coverage 
required in proteomic profiling requires hours of analysis time per sample, which limits the 
number of samples that can be run. To circumvent this, isobaric mass tags, such as iTRAQ 
(isobaric Tags for Relative and Absolute Quantitation) and TMT (Tandem Mass Tags), can 
be used to multiplex the run. 
High throughput MS-based proteomic analysis is still a relatively young technique; 
methods for protein extraction, sample preparation, and data analysis are not standardized as 
is the case for DNA or RNA sequencing. The lack of standardization results in confusion to 
those new to the field and variability in analysis results. However, MS technology is 
continuously and rapidly improving and data analysis tools are catching up. The current 
technology is sensitive enough to capture tens of thousands of proteins in a single run, and 
many software tools, both command-line and graphical user interface-based, are freely 
available for proteome bioinformatics analysis. 
A different approach to assaying the proteome, or, more accurately, the translatome, 
comprehensively is via ribosome profiling (also called ribo-seq or ribosome foot printing) or 
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polysome profiling. Though they are not the same, they both target mRNAs associated with 
polysomes, or protected by ribosome binding, respectively. These can be sequenced using 
next-gen sequencers, and reveal the subset of mRNAs being translated. However, the two 
techniques are experimentally laborious and require large amounts of starting material (82). 
1.5.2 Debate regarding gene expression regulation 
Changes in protein abundance largely determine the differences between cells, tissues 
and individuals, and are regulated at four main stages: mRNA synthesis (transcription), 
mRNA degradation, protein synthesis (translation) and protein degradation. If the rate of one 
of these is drastically different from the other three, that step would dominate in determining 
protein levels. Therefore, if mRNA synthesis and/or degradation occur at a higher rate than 
the other two, transcriptome profiling would provide an acceptable estimate of protein 
expression patterns. However, if translational control or protein degradation are the more 
prominent regulatory mechanism, only proteome profiling would give a reliable picture of 
protein expression. 
Given that proteome profiling has not reached adequate sensitivity and depth until 
recently, transcriptome profiling was the only genome-wide gene expression analysis 
approach for a long time. The advent of advanced MS instruments, however, has caused a 
paradigm shift. While discussions on the relevance of mRNA levels to protein levels have 
been around for a long time, the recent boom of MS technology has intensified the debate. 
For example, the most influential paper on the impact of transcriptional and 
translational control on protein levels is arguably that by Schwanhausser et al. (75). Cited 
nearly 3000 times since 2011, this paper aggravated the issue when it found, by measuring 
mRNA and protein abundance and turnover, that transcription and mRNA degradation only 
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account for ~ 40% of changes in protein levels at most. The implication is that transcriptome 
profiling is not a reliable way to attain protein expression patterns. 
Two years later, Li et al. (77) reanalyzed the datasets after rescaling Shwanhausser at 
al.’s estimates. The rescaling was done according to Western blot- and SILAC (Stable 
Isotope Labeling by Amino acids in Cell culture)-based measurements of protein abundance 
and by statistically accounting for technical biases introduced by RNA-seq and label-free 
proteomics. They concluded that mRNA levels explain at least 56% of protein levels. 
Furthermore, in an analysis independent of the previous one, where protein degradation rate 
was directly measured by ribosome profiling, mRNA levels were found to explain ~84% of 
the variance in protein levels. 
Battle et al. (83) profiled the transcriptomes, translatomes and proteomes of 62 
lymphoblastoid cell lines. They found protein levels to be uncorrelated to mRNA levels, and 
not largely correlated with ribosome occupancy, either. The study took a different approach 
for examining correlation: they associated genetic variants, or quantitative trait loci (QTLs), 
with proteins (pQTLs), transcripts (eQTLs), or ribosome-bound transcripts (rQTLs). eQTLs 
and rQTLs had up to 90% overlap, but pQTLs and eQTLs only had 35% overlap. 
Comparative studies support the notion that transcript levels are subject to less evolutionary 
constraints than protein levels, which agrees with Battle et al.’s finding of an attenuation of 
transcript-level changes at the protein level. 
Deviating from the debate about protein and transcript abundance, Wang et al. (78) 
profiled the proteomes and transcriptomes of three cancer cell lines. Constructing 
coexpression networks based on each -ome, they found the networks to be substantially 
different between the two. Surprisingly, coexpressed mRNAs reflected chromosomal 
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colocalization as well as functional similarity, unlike coexpressed proteins, which were only 
related based on functional similarity. This indicates that transcripts in a cell do not 
necessarily reflect function, but may simply be byproducts of the transcription of neighboring 
genes. 
An important consideration in comparing proteome and transcriptome concordance is 
whether cells or tissues being investigated are at steady-state (unperturbed) or under dynamic 
conditions (e.g. stress) (84). It generally appears that dynamic conditions disrupt proteome-
transcriptome concordance, possibly due to codon usage bias (85).  
1.6 Placental Integrative Profiling 
Despite evidence against reliance on only the proteome or only the transcriptome, an 
integrative approach incorporating proteomics in the placenta is lacking. To the best of our 
knowledge, only two studies have integrated proteomics and transcriptomics in the placenta. 
Cox et al. carried out a comparative study to define differences between human and mouse 
near-term placentas through proteome-transcriptome integration (86). They found 3085 (out 
of 6970) orthologous genes detected as transcripts in both species, but without corresponding 
protein expression. After comparing the physiochemical properties in silico of the undetected 
proteins in this set to ones detected at both the protein and RNA level, they determined that 
the absence of the proteins detected as transcripts was not due to technical limitations in MS, 
as there were no significant physiochemical differences between those undetected proteins 
and the ones detected at both levels in both species. 
To characterize the impact of assisted reproductive technology (ART) on placental 
development, Sui et al. (87) generated in vitro fertilized (IVF) embryos and in vivo fertilized 
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ones. At the blastocyst stage, embryos from both approaches were transferred to 
pseudopregnant mice. Extraembryonic tissue at e7.5 and placentas at e10.5 were collected 
and analyzed by transcriptomics and proteomics. Pearson correlations in the two timepoints 
revealed low correlation (only up to 35%) between proteome and transcriptome levels. The 
reduced correlations were exacerbated by IVF, which supports the notion that stressful 
conditions disrupt protein-RNA concordance. 
1.7 Summary 
Eaten by some (88) and worshipped by others (89), the placenta’s importance has 
always been acknowledged in one way or another. Clinically, placental abnormalities are 
responsible for many pregnancy disorders and chronic conditions (4,90). In particular, 
defects in placental trophoblast invasion, which ensures an adequate attachment of the fetus 
to the uterus and sufficient blood supply to the fetus (16), can lead to disorders such as 
placenta accreta (35), preeclampsia (30,31), and IUGR (91). Nutrient exchange is another 
placental process strongly associated with IUGR and fetal overgrowth when impaired 
(92,93). All of the previous disorders can have severe and long-term consequences on the 
mother and the baby, but most are treated by premature delivery (94–96). Despite being 
studied for decades, the causes and pathways of these disorders are still unclear, largely 
because trophoblast invasion and placental metabolism start in the first trimester, and access 
to normal human placentas before delivery is not readily available. 
To address the issue, we will use mouse as a model, as mouse placentation has many 
parallels in human, as highlighted in subsection 1.2.2 and sections 1.3 and 1.4. We plan to 
characterize the proteome and combine it with published transcriptome data (97) at two 
timepoints, one in which trophoblast invasion is predominant, and another in which 
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metabolic processes are. The proteomes of these two timepoints have not previously been 
characterized and comparing them will allow the identification of timepoint-specific 
pathways. Given that the mRNA alone does not necessarily reflect changes at the protein 
level, and proteomic technology is currently not comprehensive enough to identify the entire 
proteome, combining the transcriptome and proteome has great potential in unveiling novel 
genes involved in the regulation of these critical processes. Novel genes identified in this 
study can possibly be used as biomarkers for certain placental disorders, and/or drug targets 
for the treatment. 
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2.1 Abstract 
The condition of the placenta is a determinant of short- and long-term health of the mother as 
well as the fetus. To uncover pathways in placental development, we utilized a multi-omics 
approach, incorporating the transcriptome, proteome, and phosphoproteome of the placenta at 
embryonic day (e)7.5 and e9.5. We report the largest scale placental proteome (~6,100 
proteins) and phosphoproteome (~6,150 phosphosites). Differentially expressed proteins that 
were not differentially expressed transcripts uncovered potentially novel trophoblast invasion 
(e.g. Fermt3, Sun2, Alox12) and placental branching morphogenesis (e.g. Timeless, Yap1, 
Smad2) genes. We also observed a striking discordance between e9.5 differentially expressed 
proteins compared to differentially expressed transcripts, and propose that this may be due to 
oxidative stress after blood flow establishment. The phosphoproteome revealed novel 
conserved phosphosites on placental transcription factors (e.g. Elf3, Snai1), and allowed the 
21 
 
discovery of a putative posttranslationally regulated network at e9.5. Our results demonstrate 
how a systems-level approach can bolster standard techniques, such as RNA-seq or 
proteomics, by providing additional regulatory information that one omics alone is unlikely to 
uncover. 
2.2 Introduction 
Normal placental development is essential for a successful pregnancy, as the placenta 
harmoniously performs the roles of several organ systems simultaneously1, as well as having 
its unique functions. Understanding placental development can reveal the underlying pathways 
of many pregnancy disorders. 
Trophoblast invasion is a critical process that mediates placental, and subsequently fetal, 
attachment to the uterus, and mediates uterine spiral artery remodeling, which ensures 
sufficient blood flow to the placenta2. Defects in trophoblast invasion are associated with many 
devastating disorders, such as Preeclampsia3, intrauterine growth restriction4, and preterm 
labor5. 
Intrauterine growth restriction, which affects 5-10% of all pregnancies annually6, and fetal 
overgrowth7,8 are also associated with defects of placental nutrient transport. Unfortunately, 
both trophoblast invasion and nutrient transfer in the placenta remain poorly understood. A 
contributing factor is that the two processes start early in pregnancy, and access to normal 
human placentas before terms is difficult. 
Due to many similarities between human and mouse placentation, the mouse is an 
established model for human placental development9–11. For this reason, we utilized the mouse 
model to shed light on the development of this critical organ. Mouse trophoblast invasion starts 
early in development and peaks at e7.512, while nutrient transport across maternal and fetal 
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blood occurs after blood flow establishment, around e9.5. A thorough investigation of active 
networks and pathways at those timepoints has the potential to unveil the mechanisms by 
which trophoblast invasion and placental metabolism operate. 
Most genome-wide investigations to uncover genetic pathways employ RNA-seq, or 
transcriptome profiling, thanks to its sensitivity and cost-effectiveness. However, recent 
studies have shown that mRNA may not serve as a reliable proxy for protein expression, 
especially under dynamic conditions, such as stress15–20. 
In this study, we exploit the differences between e7.5 and e9.5 to uncover pathways 
regulating the invasion and transport functions of the placenta. To the best of our knowledge, 
we quantified the largest scale proteome acquired from a placental sample (Table S1). We also 
profiled the largest placenta phosphoproteome by far21–23. In addition, only one study before 
this had profiled the phosphoproteome at the level of the entire placenta23; previous 
publications assessed the phosphoproteome at the level of plasma membranes only22 or the 
mitochondria21. 
Leveraging high-throughput transcriptomics, proteomics and phosphoproteomics, we 
identify potentially novel genes involved in trophoblast invasion and patterning of the placenta 
(a key requirement for efficient nutrient transport). We also observe many upregulated proteins 
that had no corresponding upregulation at the transcript level, and vice versa, indicating the 
changes at the protein level are not necessarily the result of changes at the mRNA level, and 
that changes at the mRNA level do not necessarily lead to changes at the protein level. Finally, 
we discover novel phosphorylation events on transcriptions factors known to regulate placental 
processes. 
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2.3 Results 
Generation of the placental proteomes and phosphoproteomes at e7.5 and e9.5 
To identify protein networks and pathways mediating trophoblast invasion and placental 
nutrient exchange, we extracted protein from e7.5 and e9.5 placentas. Tandem mass tag 
(TMT)-labelled tryptic peptides were then analyzed by liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS) with or without phosphopeptide enrichment (Fig. 1a). 
We observed high reproducibility and accuracy in our biological replicates (Fig. 1b), as 
reflected by an average Pearson correlation of ~1 and 0.98 (based on pairwise comparisons) 
for the whole proteome and phosphoproteome replicates, respectively. Using stringent false 
discovery rate (FDR) cutoffs, we identified 7,190 proteins. After filtering out all non-quantified 
proteins (proteins without intensity values), contaminants and reverse peptides, we performed 
our analyses on the remaining 6,082 proteins (Table 1). We also identified 1,867 
phosphoproteins containing 6,161 class one (localization probability >0.75) phosphorylation 
sites, all of which were localized to a specific amino acid.  
Comparison of timepoint specific proteomes and transcriptomes 
To complement our proteomic analysis and to uncover regulatory mechanisms at e7.5 and 
e9.5, we utilized published RNA-seq data of the two timepoints24. We found 732 upregulated 
(defined as fold change ≥ 1.2, q-value < 0.05) proteins at e7.5 and 1282 at e9.5 (fold change ≤ 
0.833, q-value < 0.05). Of the total number of differentially expressed genes at e7.5 (1084 
genes), we found only ~20% overlap between differentially expressed proteins (DEPs) and 
differentially expressed transcripts (DETs) (defined as fold change ≥ 1.5 and ≤ 0.684, FPKM 
≥ 10 in the respective timepoint, q-value < 0.05) for genes detected as both transcript and 
protein (Fig. 2a and b). This indicates that changes at the transcript level do not necessarily 
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result in corresponding changes at the protein level, and that changes at the protein level may 
not be captured at the transcript level. This result was also found by Koussounadis et al.25 on a 
smaller scale.  
Functional annotation of the overlapping genes shows that they reflect known processes 
occurring at those timepoints, underscoring their importance. Enriched Gene Ontology 
biological process (GOBP) terms at e7.5 for the common differentially expressed genes 
(DEGs) were largely related to cell migration, while at e9.5, the terms were related to 
metabolism and transport (Fig. 2c). 
Investigation of differentially expressed proteins unique to the proteome 
Functional annotation of exclusive DEPs at e7.5 revealed the presence of coagulation 
processes, such as ‘coagulation’ and ‘response to wounding’ (Fig. 3), which could be a result 
of the feedback loop between the immune response, triggered by implantation and invasion, 
and coagulation. Functional annotation at e9.5 for genes differentially expressed only at the 
protein level despite being detected as transcript (exclusive DEPs) showed enrichment of terms 
related to posttranscriptional and translational regulation (Fig. 3) and the term DNA repair, a 
known consequence of stress26. 
In addition, e7.5 exclusive DEPs showed enrichment for many cell motility and migration 
terms in a redundant GO terms list (see Materials and Methods: Functional annotation). Many 
of the proteins that made up those terms in our dataset were not previously implicated in 
trophoblast invasion, based on a literature search. The overlapping ones across the redundant 
terms are Alox12, Atp8a1, Coro1a, Dmtn, Pdgfrb, Prkca, Sun2, Pla2g7, and Pf4. Their lack of 
differential transcription means that they would not stand out in a typical mRNA profiling 
workflow. Atp8a127,28, Coro1a29,30, Dmtn31–33, Pdgfrb34, and Pla2g735,36 appear to be positive 
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regulators of invasion, based on previous literature. On the other hand, Sun237,38 and Pf439,40 
have inhibitory effects on tumor migration, indicating that they may also act to keep 
trophoblast invasion in check. While Alox1241 and Prkca42,43 clearly affect cell migration, their 
influence remains unclear. We believe these proteins deserve further investigation in the 
placenta, as they may turn out to be key players in trophoblast migration. 
Similarly, e9.5 exclusive DEPs revealed genes that may play a role in placental branching 
morphogenesis (as indicated by the enriched term ‘lung development’, which was not in the 
top ten terms displayed in Fig. 3), the process by which the placenta develops its labyrinthine 
pattern to maximize nutrient exchange44. Branching morphogenesis also occurs in the lungs, 
kidneys, and mammary glands45. These proteins were Hmga2, Smad2, Timeless, Yap1, 
Sec24b. Again, they were not differentially transcribed, though their transcripts were expressed 
(FPKM >=1) in both timepoints. It is important to note that these potentially novel genes were 
not among the most abundant proteins in our proteome, and will require further validation in 
human samples. 
Characterization of the phosphoproteome at both timepoints 
Of the 6,161 high-confidence phosphopeptides quantified in our analysis, the majority were 
doubly phosphorylated, and only a fraction were triply phosphorylated (Fig. 4a). As expected, 
most of the phosphorylation events occurred at Serines (S), and only a few were detected on 
Tyrosines (Y; Fig. 4b). 826 phosphopeptides were differentially phosphorylated (t-test q-value 
< 0.05, fold change ≥ 1.2) at e7.5, while 951 were differentially phosphorylated at e9.5. 
Interestingly, about 25% of the identified phosphopeptides were phosphorylated on 
previously uncharacterized sites, based on PhosphoSitePlus46, the largest protein 
phosphorylation repository (spanning >360,000 phosphosites) (Fig. 4c). Those included 11 
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transcription factors whose phosphorylation sites were conserved in the human orthologs. 
Seven of the proteins are known or implicated in important placental processes, four at e7.5 
(Snai1, Satb2, Ets2, and Nfat5) and three at e9.5 (Elf3, E2f8, and Zeb1). The conservation of 
the novel phosphosites (examples shown in Fig. 4d) indicates their importance, but further 
research will be needed to validate and characterize their role in regulating protein activity. 
Integration of transcriptomes, proteomes and phosphoproteomes 
To expand our analysis to multiple regulatory levels, we narrowed our list of proteins to 
those detected at all three levels, a total of 1397 proteins. We then identified differential 
expression at each level and found generally little overlap between the different datasets (Fig. 
5a and b), though that differed between timepoints. Further investigation will be needed to 
determine if this result is biologically significant. 
As expected, however, despite the few proteins detected as both DEP and differentially 
expressed phosphoprotein (DEpP) at e7.5 (37; Fig. 5a), we found an enrichment of terms 
related to migration and coagulation (Fig. 5c), reinforcing the findings from overlapping DEPs 
and DETs and from exclusive DEPs at that timepoint. 
At e9.5, the top GOBP terms enriched for proteins in this category included base-excision 
repair, the prominent repair mechanism following oxidative damage47, and terms related to 
posttranslational regulation of proteins (Fig. 5c). This result provides further support for our 
hypothesis that a state of oxidative stress is a prominent feature of this timepoint that may have 
caused the greater discordance between protein and RNA compared to e7.5. In addition, the 
overlapping DEPs and DEpPs at e9.5 revealed a posttranscriptionally regulated network 
involved in HIF and VEGF signaling (Fig. 5d), suggesting the network’s participation in 
27 
 
vascularization. The network also showed enrichment of the term mTOR signaling, whose role 
in nutrient sensing has been characterized recently48,49. 
2.4 Discussion 
Placental development is an important determinant of maternal and fetal short- and long-
term health. Defects in placental processes such as trophoblast invasion and nutrient exchange 
are implicated in intrauterine growth restriction and other disorders7,8,50,51. We set out to 
investigate the genetic architecture underlying invasion and transport in the placenta. Our aim 
was to increase knowledge of normal placental development, which would allow a better 
understanding, prevention, and treatment of placental disorders. 
To this end, we used a holistic approach, integrating three layers of gene expression at two 
critical developmental timepoints: e7.5, when invasive trophoblasts are most actively invading 
maternal tissues12,52,53, and e9.5, when blood flow is established13,14. We profiled the proteomes 
and phosphoproteomes of these timepoints and utilized published transcriptome data24 to 
uncover genes participating in these functions. 
While we expected to find many timepoint-specific processes, given the differences between 
the timepoints, we were surprised that our timepoints appeared to behave differently in terms 
of gene expression regulation too. At e9.5, most of the proteins also detected as a transcript 
were only differentially expressed at the protein level (Fig. 2b), indicating a strong emphasis 
on posttranscriptional regulation at this timepoint. Stress has been shown to disrupt steady-
state gene expression regulation and therefore decrease expression correlation between 
proteins and their respective transcripts until a new steady state is established20,54. Early 
trophoblast invasion is generally associated with low levels of oxidative stress due to the 
hypoxic environment before onset of blood flow55. Once trophoblasts become intravascular, 
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however, blood pours into the placenta, causing a sharp spike in oxidative stress55,56. A 
consequence of this stress is widespread DNA damage that is mainly repaired via base-excision 
repair mechanisms26,47. 
E9.5 has been shown to be the murine timepoint at which trophoblasts become intravascular 
and blood flow is established13,14 and our findings from functional annotation of DEPs and 
DEpPs support a model in which blood flow establishment results in oxidative damage, 
incurred by a sudden increase in reactive oxygen species, and leading to a general decoupling 
of transcription and translation. 
Despite the differences between the proteome and transcriptome, common upregulated genes 
were associated with timepoint-specific functions, such as migration/invasion at e7.5 and 
metabolism/transport at e9.5 (Fig. 2b). This underscores the importance of these genes in 
carrying out their timepoint-specific processes. 
Enriched GOBP terms in the exclusive DEPs (only differentially expressed at the protein 
level, but not at the transcript) at e9.5 included lung development. Knowing that branching 
morphogenesis is a critical process for normal nutrient transport across the placenta, just as it 
is for normal oxygen and carbon dioxide exchange in the lung45, we investigated the genes in 
this term. Indeed, some of them promote lung branching morphogenesis57–67, including 
Timeless62,63, and Yap164,65, which are documented regulators of branching in the kidneys as 
well. Their differential expression at e9.5 supports our hypothesis that they may play a role in 
formation of the placental labyrinth. Further investigation of these proteins will be required to 
validate these findings. 
At e7.5, functional annotation (GOBP) revealed enrichment of terms related to migration, 
such as “regulation of cell migration”, and the genes in those terms are not, to the best of our 
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knowledge, associated with trophoblast migration in current literature. Some promote cancer 
metastasis, while others inhibit it, indicating they may be novel players in regulation of 
trophoblast migration, but this requires further study and validation.  
Beyond expression levels, posttranslational modifications influence protein conformation, 
activity, stability, etc., and it is approximated that 30% of the mammalian cellular proteome is 
phosphorylated at any given time68. While only three main amino acids can be phosphorylated 
in eukaryotes (Serine, Threonine, and Tyrosine)69,70, the phosphorylation event can have 
drastically different outcomes for protein function depending on its position in the protein. 
In our datasets, we found ~1,600 phosphosites that, according to the latest PhosphoSitePlus 
phosphorylation site dataset (update Mar 2018), were previously unknown. Seven of the 
phosphosites were differentially phosphorylated on transcription factors implicated in 
important placental processes/disorders. At e7.5, those were Snai171–74, Satb275, Ets276,77, and 
Nfat578–80. Snai1 and Nfat5 are especially interesting, as they are directly implicated in 
preeclampsia. Snai1 is usually a transcriptional repressor and phosphorylation plays a huge 
role in determining its activity and subcellular localization81. Nfat5 is constitutively nuclear, 
but different phosphorylation events can activate82,83 or repress84 its activity. Snai1 and Ets2 
were not detected in our unmodified proteome, and Nfat5 was not differentially expressed as 
an unmodified protein, further illustrating the importance of considering posttranslational 
modifications in gene expression analysis. We propose further investigation of the role of those 
sites and the kinases generating them in modulating the transcription factors’ activities.  
Unknown phosphosites at e9.5 located on placenta-related transcription factors belonged to 
Elf3, E2f8, and Zeb1. E2f8 is critical for the DNA damage response85, and E2f8/E2f7 double 
mutant mice die at e11.5, but supplying them with a wildtype placenta is sufficient to carry 
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them to term86. This indicates that placental E2f8 is a key regulator in placental and embryonic 
development, but the role of phosphorylation events in mediating its functions has not been 
sufficiently explored. Zeb1 phosphorylation, on the other hand, has been thoroughly 
investigated by Llorens et al.87. Placental Zeb1 has angiogenic properties88 and, intriguingly, 
its expression is disrupted in placentas with chromosomal aberrations, but not other placental 
abnormalities88, supporting its role in the DNA damage response89. Surprisingly, while the Elf3 
protein was upregulated at e9.5, its transcript was upregulated at e7.5, showcasing the noise 
that can be introduced by only assessing the transcriptome. E2f8 was detected as an e9.5 DET, 
but was not detected in the unmodified proteome. Zeb1 also was not detected at the protein 
level, and was not a DET despite being expressed at both timepoints (FPKM ~2). These 
phosphorylated TFs are all associated with important placental processes and are clearly under 
different levels of regulation, where phosphorylation may play a key role. We believe that 
further investigation of these sites will help shed light on signaling cascades in the placenta. 
The Hif1 signaling cascade, for example, is a prominent one in placental development. Hif1 
controls many activities in hypoxic conditions, such as those in the placenta, including glucose 
transport90 and branching morphogenesis91. It also activates the Vegf pathway92, which 
participates in similar functions93,94. Thus, it is not surprising to find the two cascades enriched 
in a network of proteins at e9.5. However, the fact that this network appears to be 
posttranscriptionally and posttranslationally regulated, highlights the importance of 
considering these regulatory layers to maximize discovery. 
We report the largest placenta proteome and phosphoproteome, as well as the first integration 
of them with the transcriptome in the placenta. Our results suggest that the placenta is dynamic 
in its regulation of gene expression; most of the proteins detected at both levels at e9.5 were 
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differentially expressed only as a protein. E7.5 also displayed a dichotomy between differential 
expression at the transcript versus the protein level. In retrospect, this is somewhat 
unsurprising, given the dynamic nature of the placenta at both timepoints; at e7.5, intense 
invasion likely incurs equally intense immune responses that must be held at bay, while at e9.5, 
the sheer stress of a sudden burst in oxygen wreaks havoc on the DNA. The confusing and 
apparently wasteful nature of why some transcripts may be differentially expressed at the 
transcript level but not at the protein is still under investigation. In the meantime, though, 
considering both the transcriptome and the proteome generally provides advantages over either 
alone. The transcriptome offers depth of coverage and sensitivity that proteome profiling still 
struggles to achieve, but proteome profiling can help eliminate noise and narrow transcriptome 
results to important genes and pathways. 
Nevertheless, we acknowledge that some limitations exist in our study. Proteomic studies 
are generally inherently biased due to technical limitations of mass spectrometry. 
Normalization helps manage biases, but cannot eliminate them completely. In addition, the 
transcriptome and (phospho)proteome were generated by different people, from different 
samples, and in different labs. This could be one of the reasons for the general lack of overlap, 
but previous transcriptome-proteome comparison studies where there were no such 
discrepancies have found little correlation in the levels of proteins and their respective 
transcripts15,25,95, which gives us more confidence in our findings. Another caveat is that much 
of the analysis is based on functional annotation, which is also biased by database and by “hot 
topics” in biology. However, our findings do fit together in a narrative that generally makes 
sense for the placenta at our timepoints. Still, future work will be carried out to validate and 
further characterize our findings. Lastly, the placenta is a heterogenous tissue, comprised of 
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many cell types, especially at e9.5 compared to e7.5. This can increase the noise in our datasets, 
but we still found expected trends and discovered putative ones, providing a first step for 
single-cell analyses to validate them and find even more. 
In conclusion, we observed that many differentially expressed transcripts are not reflected at 
the protein level and vice versa, but ones common to the two are strongly associated with 
known timepoint-specific functions, such as migration at e7.5 and transport at e9.5. 
Exploration of genes detected at both levels but only differentially expressed at the protein 
level allowed us to identify other timepoint specific mechanisms and potentially novel genes 
regulating invasion and labyrinth formation. Finally, incorporating the phosphoproteome 
complemented our findings and allowed us to zoom in to the level of individual 
phosphorylation events and discover novel ones that could play important roles in placental 
development. 
2.5 Materials and Methods 
Protein extraction 
Timed-pregnant CD-1 mice were obtained from Charles Rivers Labs and dissected at e7.5 
to obtain ectoplacental cones (EPCs) and at e9.5 to obtain placentas as described by Martin 
and Cockroft96. Staging of the mouse embryos was done according to Theiler criteria97. E7.5 
EPCs were collected in batches that were later combined to constitute ~60 per biological 
replicate, for a total of three biological replicates. Biological replicates did not overlap in any 
litters. The EPCs were snap frozen in liquid nitrogen and stored at -80ºC until extraction. Four 
e9.5 placentas were collected per biological replicate, for a total of three biological replicates. 
The placentas were snap frozen in liquid nitrogen and stored at -80ºC until extraction. 
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200µl of fresh lysis buffer (8M urea, 0.1M Tris-HCl pH 7.5, 5mM TCEP) was added to one 
tube of each replicate (e7.5 had two tubes per replicate and e9.5 had four tubes per replicate). 
The tubes were vortexed to resuspend the tissue, then mechanical disruption using beads and 
a MiniG shaker (3 minutes, 1,500 rpm) was performed to ensure efficient lysis. The contents 
of the tubes were transferred to the next tube of the respective biological replicate, and another 
200µl of lysis buffer was added, for a total of ~400µl of lysis buffer. Mechanical disruption 
was performed again for those tubes. Next, their contents were transferred to the next tube of 
the respective biological replicates before proceeding with mechanical disruption. This was 
repeated until all tubes were processed and all tubes for each replicate were combined. 
The 6 tubes (3 biological replicates for e7.5 and 3 for e9.5) were centrifuged at 4,000g for 5 
minutes at room temperature. Bradford assay (ThermoFisher) was performed on 96-well plate 
according to kit instructions to estimate protein yield (~400-500µg/ml protein per replicate at 
e7.5 and ~1000-1200µg/ml protein per replicate at e9.5). Contents were transferred to new 
tubes before centrifuging again at 12,000g for 2 minutes. Samples were then sonicated in a 
water bath for 15 minutes. 
Filter Aided Sample Preparation (FASP) was used to purify the proteins with minimal loss. 
Since the protein concentration exceeded filter (Micocon-30kDA Centrifugal Filter Unit with 
Ultracel-30 membrane, Cat # MRCF0R030) capacity, we divided each replicate between three 
filters, then made up the volume in each to 230µl. Filters were centrifuged at 12,000g for 10 
minutes. Flow-through was discarded. 200µl UA buffer (8M urea, 0.1M Tris-HCl pH 7.5) was 
added and the samples were centrifuged again and flow-through was discarded. Iodoacetamide 
(IAA) was diluted in UA buffer to 0.05M then 200µl were added to each tube and tubes were 
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incubated in the dark for 1 minute while shaking at 600rpm, then incubated for another 20 
minutes in the dark without shaking. 
Samples were centrifuged until >90% of liquid has passed through the filters (~10-20 
minutes at 12,000g). 100µl of UA buffer were added and tubes were centrifuged again for 15 
minutes at 12,000g. Flow through was discarded. Samples were washed with 0.05M 
ammonium bicarbonate (ABC) and then centrifuged at 12,000g until >90% of liquid has flown 
through the filters (10-15 minutes). This step was repeated twice, once with 200µl and once 
with 100µl, then flow through was discarded. 
Columns were transferred to new 1.5ml collection tubes. 1µg/ul trypsin was diluted 1:50 in 
0.05M ABC and added to tubes, then incubated overnight at 37ºC. The next day, Bradford 
assay was performed again to assess extent of digestion and determine how much trypsin/LysC 
mixture to add. Trypsin-LysC mixture (750µl of 0.05M ABC, 2ul of 1µg/µl trypsin and 80µl 
of 0.1µg/µl LysC) was prepared and 50µl were added to each column, and then samples were 
incubated at 37ºC for an additional 4 hours. 
Samples were centrifuged at 12,000g for 5 minutes, and 50µl of 0.05M ABC was added, 
mixed, and samples were centrifuged again. 100µl of 0.05M ABC was then added, mixed, and 
samples were centrifuged again for 10 minutes. Flow through for each replicate’s tubes was 
combined to obtain 6 tubes (3 biological replicates for e7.5 and 3 biological replicates for e9.5). 
Bicinchoninic acid assay was performed to determine peptide concentration (~100µg total 
peptides from each e7.5 replicate and ~200µg total peptides from each e9.5 replicate). Samples 
were then stored at -80ºC until C18 desalting. 
Sep-Pak C18 1 50 mg cartridges (Waters) were used for desalting, and vacuum was used to 
control flow rate through the filter. Columns were first wetted with one volume (1ml) 
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methanol, then washed twice with one volume of 0.1% formic acid without allowing column 
to dry. 100% formic acid was added to each sample to a final concentration of ~0.5% to acidify 
the samples (pH ~3, determined using Litmus paper). 1ml of 0.1% formic acid was then added 
to increase sample volumes before samples were loaded on columns and liquid was slowly 
allowed to pass through. The flow through was run on the column again to ensure maximum 
peptide retention, then discarded. Columns were then washed twice with 1ml of 0.1% formic 
acid, before eluting using increasing concentrations of acetonitrile: 250µl of 20% followed by 
250µl of 40% at a normal flow rate, and then 500µl of 80% at a slow flow rate. After elution, 
samples were concentrated via SpeedVac. 
TMT Labeling 
TMTsixplexTM   label reagents (ThermoFisher, Cat # SC244363) were used to label the 
samples, 59.35 µg vacuum dried peptides of each sample were resuspended with 100 µl 50mM 
TEAB buffer, vortexed 10 minutes at room temperature. 41µl acetonitrile was added to each 
tube of the TMT labels (0.8mg), then vortexed and incubated at room temperature for 5 minutes 
to resuspend the labels. The peptides solutions were then added to each tube of the TMT labels, 
pipetted up and down several times and vortexed to mix them well. After 2 hours incubation 
at room temperature, 8µl of 5% hydroxylamine were added to each tube, vortexed and 
incubated at room temperature for 15minutes to quench the labeling reaction. Next, the 6 
samples were mixed together and stored at -80ºC. 
Phosphopeptide enrichment 
The phosphopeptides were enriched using Titansphere Phos-TiO2 beads (GL Sciences 5010-
21315). The beads were prepared by resuspending in 1.5ml wash and binding buffer (2M lactic 
acid in 50% acetonitrile), vortexing, and then centrifuging at 3,000g for 1 minute; this was 
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repeated a total of three times. At the last step of washing, 1mg and 1.5mg TiO2 beads were 
aliquoted to new tubes before centrifugation. After centrifugation, the wash and binding buffer 
were removed and the TiO2 beads were saved for the next phosphopeptide enrichment. 300µg 
TMT6-labeled and vacuum dried peptides were resuspended with 300µl wash and binding 
buffer and then added to 1.5mg TiO2 beads, rotated at room temperature for 1 hour, and then 
centrifuged at 3,000g for 1 minute. The supernatant was then processed with a second round 
of enrichment using 1mg of TiO2 beads. 1.8ml wash and binding buffer was added to each tube 
of the two enrichment steps, vortexed and centrifuged at 3,000g for 1 minute. This wash was 
repeated once. Next, the TiO2 beads were washed twice with 1.8ml of 50% acetonitrile in 0.1% 
TFA. After the wash steps, 500µl of 3% ammonium hydroxide was added to each tube of the 
two enrichment steps, vortexed and centrifuged at 3,000g for 1 minute. The eluted supernatants 
were combined. One more elution step was performed with 5% ammonium hydroxide this 
time. All the supernatants from the two elution steps were combined together and SpeedVac’ed 
to dry, and then the phosphopeptides were resuspended in 0.1% FA, and stored at -80ºC until 
the LC/MS-MS run. 
LC/MS-MS 
An Agilent 1260 quaternary HPLC was used to deliver a flow rate of ~600 nL min-1 via a 
splitter. All columns were packed in house using a Next Advance pressure cell and the 
nanospray tips were fabricated using fused silica capillary that was pulled to a sharp tip using 
a laser puller (Sutter P-2000). 45g of TMT-labeled peptides (non-modified proteome) or all 
TiO2 enriched peptides (phosphoproteome) were loaded unto 20cm capillary columns packed 
with 5μM Zorbax SB-C18 (Agilent), which was connected using a zero dead volume 1μm 
filter (Upchurch, M548) to a 5cm long strong cation exchange (SCX) column packed with 
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5μm PolySulfoethyl (PolyLC). The SCX column was then connected to a 20cm nanospray 
tip packed with 2.5μM C18 (Waters). The 3 sections were joined and mounted on a custom 
electrospray source for on-line nested peptide elution. A new set of columns was used for 
every sample. Peptides were eluted from the loading column unto the SCX column using a 0 
to 80% acetonitrile (ACN) gradient over 60 minutes. Peptides were then fractionated from 
the SCX column using a series of salt steps. For the non-modified proteome, the following 
ammonium acetate salt steps were used: 10, 25, 30, 32.5, 34, 36, 38, 42, 44, 46, 48, 50, 52, 
55, 57, 60, 65, 70, 75, 80, 90, 98, 100, 110, 130, 150, and 1000 mM. For the 
phosphoproteome analysis, the following ammonium acetate steps of 30, 80, and 100 mM 
were used. For these analyses, buffers A (99.9% H2O, 0.1% formic acid), B (99.9% ACN, 
0.1% formic acid), C (100 mM ammonium acetate, 2% formic acid), and D (2M ammonium 
acetate, 2% formic acid) were utilized. For each salt step, a 150 min gradient program 
comprised of a 0-5 min increase to the specified ammonium acetate concentration, 5-10 min 
hold, 10-14 min at 100% buffer A, 15-120 min 5-35% buffer B, 120-140 min 35-80% buffer 
B, 140-145 min 80% buffer B, and 145-150 min buffer A was employed. 
Eluted peptides were analyzed using a Thermo Scientific Q-Exactive Plus high-resolution 
quadrupole Orbitrap mass spectrometer, which was directly coupled to the HPLC. Data 
dependent acquisition was obtained using Xcalibur 4.0 software in positive ion mode with a 
spray voltage of 2.00 kV and a capillary temperature of 275 °C and an RF of 60. MS1 spectra 
were measured at a resolution of 70,000, an automatic gain control (AGC) of 3e6 with a 
maximum ion time of 100 ms and a mass range of 400-2000 m/z. Up to 15 MS2 were 
triggered at a resolution of 17,500 with a fixed first mass of 120 m/z. An AGC of 1e5 with a 
maximum ion time of 50 ms, an isolation window of 1.3 m/z, and a normalized collision 
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energy of 31 and 32 were used for non-modified and phospho- proteomes, respectively. 
Charge exclusion was set to unassigned, 1, 5-8, and >8. MS1 that triggered MS2 scans were 
dynamically excluded for 25 or 30 s for non-modified and phospho proteomes, respectively.  
Database search and FDR filtering 
The raw data were analyzed using MaxQuant version 1.6.0.16 98. Spectra were searched 
against the GRCm38.p5 Ensembl genome assembly, which was complemented with reverse 
decoy sequences and common contaminants by MaxQuant. Carbamidomethyl cysteine was 
set as a fixed modification while methionine oxidation and protein N-terminal acetylation 
were set as variable modifications. Digestion parameters were set to “specific” and 
“Trypsin/P;LysC”. Up to two missed cleavages were allowed. A false discovery rate less 
than 0.01 at both the peptide spectral match and protein identification level was required. The 
‘second peptide’ option was on to identify co-fragmented peptides. The match between runs 
feature of MaxQuant was not utilized. 
Data normalization and filtering 
Unmodified proteome (‘proteinGroups.txt’ MaxQuant output) were normalized using 
Normalyzer global median intensity (MedI) normalization99. Using Perseus100,101 version 
1.6.1.1, we imported the data and then filtered out potential contaminants and reverse peptides. 
In addition, only proteins that were quantified in all samples were kept in the unmodified 
proteome (leaving 6,174 proteins). For the phosphoproteome (‘Phsopho (STY)Sites.txt’ 
MaxQuant output), we used Perseus to filter out contaminants, reverse peptides, and class two 
and three phosphosites (localization probability ≤ 0.75) to leave only high confidence 
phosphorylation events. We then expanded the table before normalizing so as not to introduce 
bias. Normalization was the same as the unmodified proteome. We imported the normalized 
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dataset to Perseus and filtered out phosphosites not quantified in all biological replicates of at 
least one timepoint (leaving 6,161 phosphosites). 
Statistical analysis 
Perseus was used for statistical data analysis and heatmaps. Hierarchical clustering heatmaps 
were generated using Perseus’s default settings (Euclidean distance, average linkage, k-means 
processing, 300 clusters, and maximum of 10 iterations) after Z-score normalization without 
grouping the replicates. Differential expression for both proteomes was determined using a 
two-sample Student’s t-test with default settings (P-values were corrected with a permutation-
based FDR with an FDR cutoff of 0.05 and 250 permutations) Proteins were considered 
differentially expressed if the FDR was < 0.05 and the fold change was ≥ 1.2 or ≤ 0.83. 
Transcriptome analysis 
Analyzed mRNA-seq data generated with three biological replicates of each timepoint was 
obtained from Tuteja et al.24. FPKM values < 1 were considered not expressed, and the data 
was filtered to remove genes with FPKM <1 in both timepoints. Differential expression was 
determined based on an FPKM ≥ 10 in the respective timepoint, on statistical significance (q-
value <0.05), and on a fold change ≥ 1.5 or ≤ 0.667, and. 
Proteome-transcriptome integration 
The MaxQuant output for the proteome had identifiers in the form of Ensembl protein stable 
IDs with version (e.g. ENSMUSP00000000001.4) and gene name (e.g. hypoxia inducible 
factor 1, alpha subunit), while the RNA-seq data had identifiers in the form of Mouse Genome 
Informatics (MGI) symbols (e.g. Hif1a). To be able to match the two datasets, we converted 
Ensembl IDs to MGI symbols. The biomaRt R package102,103 was used to convert the first 
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identifier in each row of the “Majority Peptide IDs” column to its respective MGI symbol. IDs 
that were not mapped (~23) were looked up manually using the gene name. 
Using R, we matched the newly-obtained gene symbols for the proteome and transcriptome 
to identify genes expressed at both levels. At this stage, we found some IDs that did not map 
due to use of a gene symbol synonym rather than the current name. Those were looked up in 
the Mouse Genome Database through MGI website104 using R, and then the synonymous 
symbols in the RNA file were replaced with the current symbols also using R. Venn Diagrams 
were generated with the VennDiagram R package105. 
Functional annotation 
WebGestalt106,107 overrepresentation analysis was used for all Gene Ontology Biological 
Process annotations. The reference gene set was “genome_protein-coding”, the Functional 
database was ‘geneontology’ and the functional database name was either 
‘Biological_Process’ for a list of all enriched terms, regardless of redundancy, or 
‘Biological_Process_noRedundant’ for a list of only non-redundant enriched terms. Advanced 
parameters were left to defaults, except that significance level was set to an FDR cutoff of 
0.05. Non-redundant lists were utilized in most analyses and visualizations. Redundant lists 
were used in the analysis associated with Fig. 5c, because there was only one non-redundant 
enriched term at e9.5 for the set of upregulated and differentially phosphorylated proteins. 
In addition, potentially novel genes were found by looking at redundant lists (see Appendix, 
Tables A5 and A6). At e7.5, we looked for genes common among redundant motility/migration 
terms, specifically Regulation of cell motility, Regulation of cell migration, Regulation of 
locomotion, Cell migration, Cell motility, Locomotion, Positive regulation of cell migration, 
Positive regulation of locomotion, Positive regulation of cell motility, Granulocyte migration, 
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and Leukocyte migration. A gene was selected as a putative novel gene if it was common in at 
least 9 of the 11 terms, if a web search revealed that it was involved in invasion or migration, 
and if a web search could not find evidence to it being involved in invasion or migration in the 
placenta. At e9.5, the redundant list had an enrichment for the term ‘Lung development’, from 
which putative novel branching genes were selected. A gene was selected if a web search 
revealed its involvement in branching of any tissue, and if there was no evidence that it was 
involved in branching in the placenta. 
Enrichment of KEGG pathways for proteins in the posttranscriptionally regulated network 
in Fig. 5d was downloaded from STRING108 and plotted in R using the ggplot2109 package. 
Phosphoproteome analysis 
After the normalization and filtering steps carried out above, pie charts were created using 
meta-chart.com with modifications. Known sites were identified through Perseus based on the 
latest update (Mar 16, 2018) of the phosphorylation site dataset from PhosphoSitePlus. Kinase 
substrate motifs were identified through Perseus based on the latest update (Mar 16, 2018) of 
the kinase substrate dataset. Conservation of phosphosites was found by BLASTing the 
phosphopeptide sequence (obtained from “sequence window” column in the ‘phospho 
(STY)Sites.txt’ file) in Uniprot110. 
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FIGURES 
 
Figure 1. (a) experimental design. (b) hierarchical clustering of proteome and 
phosphoproteome biological replicates at e7.5 and e9.5. 
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Figure 2. (a,b) Overlap of DEPs and DETs for genes detected as protein and transcript at e7.5 
(a) and at e9.5 (b). (c) Heatmap representing significantly enriched Gene Ontology Biological 
Process (GOBP) terms for genes differentially expressed at the protein and transcript level. 
DET, differentially expressed transcript; DEP, differentially expressed protein; e, embryonic 
day; GOBP, Gene Ontology Biological Process. 
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Figure 3. Heatmap representing significantly enriched Gene Ontology Biological Process 
(GOBP) terms for genes differentially expressed at the protein level only, despite being 
quantified at the transcript level (FPKM ≥1). e, embryonic day; GOBP, Gene Ontology 
Biological Process. 
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Figure 4. Summary of findings from the phosphoproteome. (a) number of phosphorylation 
events at individual phosphosites. (b) Distribution of phosphorylation events at Serines (S), 
Threonines (T), and Tyrosines (Y). (c) Proportion of previously characterized and 
uncharacterized phosphosites in our dataset. Based on PhosphoSitePlus46. (d) Examples of 
transcription factors implicated in important placental processes with previously unknown but 
conserved (in red) phosphosites; light green represents unconserved amino acids. S, Serine; T, 
Threonine; Y, Tyrosine. 
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Figure 5. Integration of transcriptomes, proteomes and phosphoproteomes at e7.5 (a) and e9.5 
(b). (c) Enriched Gene Ontology Biological Process (GOBP) terms for e9.5 differentially 
expressed and differentially phosphorylated proteins that were not differentially expressed at 
the transcript level. (d) STRING protein-protein-interaction network based on the e9.5 
differentially expressed and differentially phosphorylated proteins that were not differentially 
expressed at the transcript level, along with enriched KEGG pathways for the network. Colors 
in the network represent the corresponding enriched term. DEpP, differentially expressed 
phosphoprotein; DET, differentially expressed transcript; DEP, differentially expressed 
protein; e, embryonic day; FDR, false discovery rate. 
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TABLES  
Table 1. Summary of acquired spectra, peptides, and proteins.  
 Collected 
spectra 
Identified 
spectra 
Unique 
peptides 
Proteins 
Non-modified 
proteome 
1,483,516 362,509 57,562 6,082 
Phosphoproteome 167,562 21,770 4,860 1,866 
Total 1,651,078 384,279 62,422 7,949 
 
2.6 Supplementary Information 
Table S1. Placenta whole proteome studies and number of proteins quantified in each study. 
Paper Number of proteins found 
Cox et al. (2009)11 Mouse placenta: 4662 
Human placenta: 4612 
Gharesi-Fard et al. (2014)111 Human placenta: 1270 
Wang et al. (2013)112 Human placenta: 2636 
Sui et al. (2014)113 Mouse placenta: 969* 
Lee et al. (2013)23 Human placenta: 4239 
Miao et al. (2014)114 Human placenta: 1198 
Lee et al. (2015)115 Pig placenta: 945* 
Heywood et al. (2017)116 Human placenta: 1096 
Moriyama et al. (2017)117 Human placenta: 1327 
Mine et al. (2007)118 Human placenta: 450* 
Pan et al. (2018)119 Human placenta: 2805 
Gharesi-Fard et al. (2010)120 Human placenta: 1275* 
Mary et al. (2017)121 Human placenta: 2145 
* maximum number from different treatments and/or timepoints 
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CHAPTER 3. GENERAL CONCLUSIONS 
This study highlights the advantages of a multi-omics approach to the 
characterization of networks and pathways existing in a cell or tissue. The human placenta is 
a difficult organ to study at the early stages because few samples are available before 
delivery. Understanding placental development is, however, crucial, as the placenta exerts 
maternal effects on the fetus that may be carried for life, and defects in its function can have 
devastating effects on maternal health. There remains a need for biomarkers and drug targets 
for the discovery and treatment of placental disorders. 
Our analysis is a step forward in that direction. Using mouse placenta, we generated 
the largest reported placenta proteome and phosphoproteome, which allowed us to discover 
potentially novel genes and phosphosites that may play a role in critical placental processes. 
We also identified processes parallel to those found in previous literature that furthered our 
understanding of murine placental development, which is an established model for human 
placentation. This information could not have been obtained from any of the individual datasets 
alone with the same confidence and not at all in some cases, emphasizing the benefits of 
incorporating different levels of gene expression regulation. 
We acknowledge that our study has limitations. For example, bias in the proteome due 
to technical limitations of proteomic technology; noise in the datasets due the cellular 
heterogeneity of the placenta; lack of strong evidence due to absence of extensive 
bioinformatic, statistical and experimental analyses; and possibly distorted findings due to the 
use of published transcriptome data rather than generating our own. 
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To overcome the limitations, future directions include incorporating single-cell multi-
omics analyses to reduce noise. Analyzing invasive TGCs (Prl3d1+ cells) in both timepoints 
has the potential to reveal an unprecedented level of information regarding trophoblast 
invasion, for example. In addition, a stronger experimental design with more biological 
replicates will allow for more extensive statistical and bioinformatic analysis, such as 
coexpression analysis and the construction of gene regulatory networks. Finally, experimental 
validation is an essential aspect of future directions. Mouse knockouts of the genes identified 
in this study should be investigated for placental abnormalities associated with their putative 
function. In addition, the cell culture system and Matrigel invasion assays can be utilized to 
test for the impact of knocking down or overexpressing genes on invasive potential. The 
phosphosites can be mutated to phosphomimetic sites to validate and investigate the role of the 
sites in placental development. Finally, these findings should also be validated in human cell 
lines and placentas. 
In summary, we utilized a systems-level integrative approach at two crucial timepoints 
of murine placentation to uncover regulatory differences between the timepoints. We identified 
genes that may be novel participants in invasion or nutrient transport, and novel phosphosites 
that may regulate the function of critical placental transcription factors. 
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ABBREVIATIONS 
DEP   Differentially Expressed Protein 
DET   Differentially Expressed Transcript 
DEpP   Differentially Expressed Phosphoprotein 
p.c.   post coitum 
e   embryonic day 
IUGR   Intrauterine Growth Restriction 
EVT   Extravillous Trophoblast 
TGC   Trophoblast Giant Cell 
TGFβ   Transforming Growth Factor Beta 
FGF4   Fibroblast Growth Factor 4 
MMP   Matrix Metalloproteinase 
iEVT   interstitial Extravillous Trophoblast 
enEVT   endovascular Extravillous Trophoblast 
TF   Transcription Factor 
hCG   human Chorionic Gonadotropin 
RNA   Ribonucleic Acid 
DNA   Deoxyribonucleic Acid 
ECM   Extracellular Matrix 
p-TGC   parietal Trophoblast Giant Cell 
TSC   Trophoblast Stem Cell 
ch-TGC  channel Trophoblast Giant Cell 
spA-TGC  spiral Artery Trophoblast Giant Cell 
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c-TGC   canal Trophoblast Giant Cell 
s-TGC   sinusoidal Trophoblast Giant Cell 
mRNA   messenger Ribonucleic Acid 
RNA-seq  Ribonucleic Acid sequencing 
LC-MS/MS  Liquid Chromatography Tandem Mass Spectrometry 
cDNA   complimentary DNA 
iTRAQ  isobaric Tag for Relative and Absolute Quantitation 
TMT   Tandem Mass Tag 
MS   Mass spectrometry 
SILAC   Stable Isotope Labelling by Amino acids in Cell culture 
QTL   Quantitative Trait Loci 
ART   Assisted Reproductive Technology 
IVF   In-Vitro Fertilization 
FDR   False Discovery Rate 
FPKM   Fragments Per Kilobase Mapped 
DEG   Differentially Expressed Gene 
GOBP   Gene Ontology Biological Process 
EPC   Ectoplacental Cone 
IAA   Iodoacetamide 
ABC   Ammonium Bicarbonate 
MedI   Median Intensity 
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APPENDIX. GENE ONTOLOGY TERMS 
Table A1. List of Gene Ontology Biological Process non-redundant terms for e7.5 common DEPs and DETs 
geneset description PValue FDR 
GO:0061458 reproductive system development 1.67E-07 0.000119 
GO:0001667 ameboidal-type cell migration 4.27E-07 0.000152 
GO:0051271 negative regulation of cellular component 
movement 
1.24E-06 0.000296 
GO:0040013 negative regulation of locomotion 2.27E-06 0.000405 
GO:0001701 in utero embryonic development 3.28E-06 0.000468 
GO:0048514 blood vessel morphogenesis 1.10E-05 0.001177 
GO:0090130 tissue migration 1.15E-05 0.001177 
GO:0048771 tissue remodeling 1.32E-05 0.00118 
GO:0031589 cell-substrate adhesion 2.09E-05 0.001661 
GO:0007015 actin filament organization 2.57E-05 0.001833 
GO:0002064 epithelial cell development 3.70E-05 0.002399 
GO:0009611 response to wounding 6.14E-05 0.003599 
GO:0035239 tube morphogenesis 7.03E-05 0.003599 
GO:0044706 multi-multicellular organism process 7.06E-05 0.003599 
GO:0050673 epithelial cell proliferation 7.83E-05 0.003729 
GO:0051235 maintenance of location 0.000132 0.005903 
GO:0032102 negative regulation of response to external stimulus 0.000147 0.006173 
GO:0002009 morphogenesis of an epithelium 0.000159 0.006313 
GO:1901342 regulation of vasculature development 0.000184 0.006912 
GO:0034330 cell junction organization 0.000276 0.009499 
GO:0010638 positive regulation of organelle organization 0.000279 0.009499 
GO:0048638 regulation of developmental growth 0.000305 0.009892 
GO:0032970 regulation of actin filament-based process 0.000324 0.010036 
GO:0016049 cell growth 0.000337 0.010036 
GO:0042330 taxis 0.0004 0.011435 
GO:0001503 ossification 0.000452 0.01234 
GO:0007163 establishment or maintenance of cell polarity 0.000467 0.01234 
GO:0040017 positive regulation of locomotion 0.000484 0.01234 
GO:0048568 embryonic organ development 0.000577 0.013935 
GO:0008637 apoptotic mitochondrial changes 0.000594 0.013935 
GO:0090066 regulation of anatomical structure size 0.000605 0.013935 
GO:0042476 odontogenesis 0.000872 0.019458 
GO:0051272 positive regulation of cellular component 
movement 
0.000963 0.020829 
GO:0043112 receptor metabolic process 0.001166 0.024279 
GO:0045927 positive regulation of growth 0.00119 0.024279 
GO:0051493 regulation of cytoskeleton organization 0.001226 0.024314 
GO:0071526 semaphorin-plexin signaling pathway 0.00128 0.0247 
GO:0050900 leukocyte migration 0.001319 0.024793 
72 
 
GO:0002697 regulation of immune effector process 0.001359 0.024877 
GO:0044089 positive regulation of cellular component 
biogenesis 
0.001583 0.028252 
GO:0071496 cellular response to external stimulus 0.001855 0.032305 
GO:0031214 biomineral tissue development 0.002071 0.035204 
GO:0002521 leukocyte differentiation 0.002413 0.040073 
GO:0021675 nerve development 0.002527 0.040608 
GO:0044723 single-organism carbohydrate metabolic process 0.002559 0.040608 
GO:0010035 response to inorganic substance 0.00302 0.046869 
GO:0001763 morphogenesis of a branching structure 0.003222 0.048941 
GO:0002526 acute inflammatory response 0.003349 0.049702 
GO:0007229 integrin-mediated signaling pathway 0.003429 0.049702 
GO:0048863 stem cell differentiation 0.003481 0.049702 
Table A2. List of Gene Ontology Biological Process non-redundant terms for e9.5 common DEPs and DETs 
geneset description PValue FDR 
GO:0016042 lipid catabolic process 3.19E-07 0.000228 
GO:0008202 steroid metabolic process 1.04E-06 0.000372 
GO:0097164 ammonium ion metabolic process 1.14E-05 0.00272 
GO:0051180 vitamin transport 8.01E-05 0.014293 
GO:0006898 receptor-mediated endocytosis 0.000183 0.024826 
GO:0030258 lipid modification 0.000209 0.024826 
GO:0097006 regulation of plasma lipoprotein particle levels 0.000327 0.030772 
GO:0044282 small molecule catabolic process 0.000345 0.030772 
GO:0035272 exocrine system development 0.000536 0.042495 
Table A3. List of Gene Ontology Biological Process non-redundant terms for e7.5 exclusive DEPs 
geneset description PValue FDR 
GO:0050817 coagulation 2.08E-14 1.48E-11 
GO:0050878 regulation of body fluid levels 1.94E-10 5.57E-08 
GO:0009611 response to wounding 2.34E-10 5.57E-08 
GO:0006790 sulfur compound metabolic process 8.34E-08 1.49E-05 
GO:0007229 integrin-mediated signaling pathway 3.90E-07 5.57E-05 
GO:0034109 homotypic cell-cell adhesion 2.54E-06 0.000302 
GO:0010035 response to inorganic substance 4.10E-06 0.000418 
GO:0031589 cell-substrate adhesion 7.44E-06 0.000664 
GO:0072593 reactive oxygen species metabolic process 1.16E-05 0.000923 
GO:0006091 generation of precursor metabolites and 
energy 
1.42E-05 0.000959 
GO:0006575 cellular modified amino acid metabolic 
process 
1.48E-05 0.000959 
GO:0006631 fatty acid metabolic process 1.80E-05 0.001072 
GO:0046486 glycerolipid metabolic process 2.32E-05 0.001274 
GO:0072350 tricarboxylic acid metabolic process 3.21E-05 0.001639 
GO:1901615 organic hydroxy compound metabolic process 4.12E-05 0.001962 
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GO:0002237 response to molecule of bacterial origin 7.38E-05 0.003292 
GO:0048871 multicellular organismal homeostasis 8.07E-05 0.003391 
GO:0006979 response to oxidative stress 9.41E-05 0.003598 
GO:0048872 homeostasis of number of cells 9.68E-05 0.003598 
GO:0051186 cofactor metabolic process 0.000101 0.003598 
GO:1901565 organonitrogen compound catabolic process 0.000143 0.004866 
GO:0009636 response to toxic substance 0.000237 0.007689 
GO:0031532 actin cytoskeleton reorganization 0.000315 0.009769 
GO:0042493 response to drug 0.000376 0.01119 
GO:0006638 neutral lipid metabolic process 0.000419 0.011968 
GO:0033013 tetrapyrrole metabolic process 0.000458 0.012257 
GO:0072521 purine-containing compound metabolic 
process 
0.00048 0.012257 
GO:0051051 negative regulation of transport 0.000481 0.012257 
GO:1901657 glycosyl compound metabolic process 0.000771 0.018976 
GO:0030099 myeloid cell differentiation 0.001229 0.029248 
GO:0045454 cell redox homeostasis 0.001286 0.029622 
GO:2001233 regulation of apoptotic signaling pathway 0.00135 0.030114 
GO:0044283 small molecule biosynthetic process 0.00144 0.031147 
GO:0097734 extracellular exosome biogenesis 0.001542 0.032382 
GO:0030258 lipid modification 0.001968 0.039303 
GO:0009123 nucleoside monophosphate metabolic process 0.001982 0.039303 
GO:0019693 ribose phosphate metabolic process 0.002188 0.042217 
GO:0015748 organophosphate ester transport 0.002558 0.048059 
Table A4. List of Gene Ontology Biological Process non-redundant terms for e9.5 exclusive DEPs 
geneset description PValue FDR 
GO:0034248 regulation of cellular amide metabolic process 6.98E-11 4.99E-08 
GO:0010608 posttranscriptional regulation of gene 
expression 
2.78E-10 9.93E-08 
GO:0006511 ubiquitin-dependent protein catabolic process 2.72E-09 4.70E-07 
GO:0006413 translational initiation 2.89E-09 4.70E-07 
GO:0071826 ribonucleoprotein complex subunit 
organization 
3.29E-09 4.70E-07 
GO:0002181 cytoplasmic translation 8.06E-09 9.59E-07 
GO:0022613 ribonucleoprotein complex biogenesis 4.79E-08 4.89E-06 
GO:0016569 covalent chromatin modification 5.84E-08 5.21E-06 
GO:0006281 DNA repair 1.40E-07 1.11E-05 
GO:0048193 Golgi vesicle transport 1.13E-05 0.00081 
GO:0006260 DNA replication 1.47E-05 0.000956 
GO:0031365 N-terminal protein amino acid modification 5.63E-05 0.003329 
GO:0070670 response to interleukin-4 6.06E-05 0.003329 
GO:0010498 proteasomal protein catabolic process 0.000134 0.006389 
GO:0051276 chromosome organization 0.000134 0.006389 
GO:0016482 cytosolic transport 0.000171 0.007623 
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GO:0007067 mitotic nuclear division 0.0002 0.008249 
GO:0000209 protein polyubiquitination 0.000208 0.008249 
GO:0018210 peptidyl-threonine modification 0.000317 0.01192 
GO:2001020 regulation of response to DNA damage 
stimulus 
0.000512 0.018294 
GO:0006333 chromatin assembly or disassembly 0.000563 0.019136 
GO:0032259 methylation 0.000677 0.021705 
GO:0006513 protein monoubiquitination 0.000712 0.021705 
GO:1990089 response to nerve growth factor 0.00073 0.021705 
GO:0051052 regulation of DNA metabolic process 0.001104 0.031516 
GO:0051169 nuclear transport 0.001198 0.032906 
GO:0008213 protein alkylation 0.001415 0.036421 
GO:0006338 chromatin remodeling 0.001428 0.036421 
GO:0018205 peptidyl-lysine modification 0.001753 0.043162 
GO:0034660 ncRNA metabolic process 0.002086 0.049659 
Table A5. List of Gene Ontology Biological Process redundant terms for e7.5 exclusive DEPs 
geneset description PValue FDR 
GO:0007596 blood coagulation 0 0 
GO:0007599 hemostasis 0 0 
GO:0044281 small molecule metabolic process 0 0 
GO:0050817 coagulation 0 0 
GO:0055114 oxidation-reduction process 0 0 
GO:1901564 organonitrogen compound metabolic process 4.11E-15 5.70E-12 
GO:0042060 wound healing 5.55E-15 6.61E-12 
GO:0009611 response to wounding 4.86E-14 5.06E-11 
GO:0050878 regulation of body fluid levels 1.37E-13 1.27E-10 
GO:0006629 lipid metabolic process 2.19E-12 1.82E-09 
GO:0043436 oxoacid metabolic process 4.28E-12 3.24E-09 
GO:0006082 organic acid metabolic process 8.93E-12 6.00E-09 
GO:0045333 cellular respiration 9.36E-12 6.00E-09 
GO:0030168 platelet activation 1.15E-11 6.85E-09 
GO:0019752 carboxylic acid metabolic process 1.45E-11 8.04E-09 
GO:0044255 cellular lipid metabolic process 1.16E-10 6.06E-08 
GO:0042592 homeostatic process 1.66E-10 8.11E-08 
GO:0030193 regulation of blood coagulation 1.89E-10 8.27E-08 
GO:1900046 regulation of hemostasis 1.89E-10 8.27E-08 
GO:0006790 sulfur compound metabolic process 2.80E-10 1.17E-07 
GO:0022904 respiratory electron transport chain 4.30E-10 1.71E-07 
GO:0050818 regulation of coagulation 5.43E-10 2.06E-07 
GO:0061041 regulation of wound healing 6.49E-10 2.35E-07 
GO:0022900 electron transport chain 1.10E-09 3.82E-07 
GO:0044248 cellular catabolic process 2.70E-09 8.99E-07 
GO:0070527 platelet aggregation 4.55E-09 1.46E-06 
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GO:0015980 energy derivation by oxidation of organic compounds 5.32E-09 1.64E-06 
GO:1903034 regulation of response to wounding 8.94E-09 2.66E-06 
GO:0010035 response to inorganic substance 1.09E-08 3.14E-06 
GO:0001775 cell activation 1.14E-08 3.17E-06 
GO:0006749 glutathione metabolic process 1.25E-08 3.35E-06 
GO:0002376 immune system process 1.40E-08 3.64E-06 
GO:0007229 integrin-mediated signaling pathway 1.73E-08 4.37E-06 
GO:0009056 catabolic process 2.55E-08 6.25E-06 
GO:0019637 organophosphate metabolic process 2.67E-08 6.37E-06 
GO:0031589 cell-substrate adhesion 7.53E-08 1.74E-05 
GO:0009060 aerobic respiration 8.25E-08 1.86E-05 
GO:0006461 protein complex assembly 9.60E-08 2.10E-05 
GO:0070271 protein complex biogenesis 9.87E-08 2.11E-05 
GO:0071822 protein complex subunit organization 1.03E-07 2.15E-05 
GO:0009605 response to external stimulus 1.25E-07 2.49E-05 
GO:0006631 fatty acid metabolic process 1.25E-07 2.49E-05 
GO:0006091 generation of precursor metabolites and energy 1.31E-07 2.49E-05 
GO:0010038 response to metal ion 1.31E-07 2.49E-05 
GO:0042775 mitochondrial ATP synthesis coupled electron transport 1.35E-07 2.50E-05 
GO:0034109 homotypic cell-cell adhesion 1.50E-07 2.72E-05 
GO:1990748 cellular detoxification 1.64E-07 2.90E-05 
GO:0048878 chemical homeostasis 1.91E-07 3.31E-05 
GO:0072593 reactive oxygen species metabolic process 2.03E-07 3.46E-05 
GO:0043603 cellular amide metabolic process 2.44E-07 4.07E-05 
GO:0051188 cofactor biosynthetic process 2.57E-07 4.18E-05 
GO:0046486 glycerolipid metabolic process 2.66E-07 4.18E-05 
GO:0019725 cellular homeostasis 2.71E-07 4.18E-05 
GO:0032787 monocarboxylic acid metabolic process 2.74E-07 4.18E-05 
GO:1901615 organic hydroxy compound metabolic process 2.76E-07 4.18E-05 
GO:0098754 detoxification 2.99E-07 4.46E-05 
GO:0044711 single-organism biosynthetic process 3.11E-07 4.55E-05 
GO:0042773 ATP synthesis coupled electron transport 3.60E-07 5.17E-05 
GO:0055086 nucleobase-containing small molecule metabolic process 4.28E-07 6.01E-05 
GO:0042743 hydrogen peroxide metabolic process 4.33E-07 6.01E-05 
GO:2001234 negative regulation of apoptotic signaling pathway 5.07E-07 6.92E-05 
GO:0006575 cellular modified amino acid metabolic process 5.35E-07 7.18E-05 
GO:0050801 ion homeostasis 7.62E-07 0.000101 
GO:0006979 response to oxidative stress 9.55E-07 0.000122 
GO:1901575 organic substance catabolic process 9.55E-07 0.000122 
GO:0002237 response to molecule of bacterial origin 9.75E-07 0.000123 
GO:0006066 alcohol metabolic process 1.04E-06 0.000124 
GO:0006099 tricarboxylic acid cycle 1.04E-06 0.000124 
GO:0010543 regulation of platelet activation 1.04E-06 0.000124 
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GO:0098869 cellular oxidant detoxification 1.04E-06 0.000124 
GO:0048871 multicellular organismal homeostasis 1.08E-06 0.000127 
GO:0007010 cytoskeleton organization 1.32E-06 0.000153 
GO:0051186 cofactor metabolic process 1.39E-06 0.000158 
GO:0032496 response to lipopolysaccharide 1.77E-06 0.000199 
GO:0048872 homeostasis of number of cells 1.80E-06 0.0002 
GO:0032101 regulation of response to external stimulus 1.84E-06 0.000202 
GO:0065003 macromolecular complex assembly 2.29E-06 0.000248 
GO:0006101 citrate metabolic process 2.67E-06 0.000285 
GO:0030194 positive regulation of blood coagulation 2.90E-06 0.000302 
GO:1900048 positive regulation of hemostasis 2.90E-06 0.000302 
GO:1901565 organonitrogen compound catabolic process 3.26E-06 0.000336 
GO:0007160 cell-matrix adhesion 3.37E-06 0.000342 
GO:0046128 purine ribonucleoside metabolic process 4.74E-06 0.000476 
GO:0072521 purine-containing compound metabolic process 4.82E-06 0.000478 
GO:0009117 nucleotide metabolic process 4.87E-06 0.000478 
GO:0072350 tricarboxylic acid metabolic process 4.96E-06 0.00048 
GO:0042493 response to drug 5.45E-06 0.000522 
GO:0042278 purine nucleoside metabolic process 5.83E-06 0.000552 
GO:0006119 oxidative phosphorylation 6.24E-06 0.000584 
GO:0051051 negative regulation of transport 6.33E-06 0.000586 
GO:0061045 negative regulation of wound healing 6.55E-06 0.000588 
GO:0016337 single organismal cell-cell adhesion 6.55E-06 0.000588 
GO:0050820 positive regulation of coagulation 6.56E-06 0.000588 
GO:0042744 hydrogen peroxide catabolic process 6.78E-06 0.000601 
GO:0006753 nucleoside phosphate metabolic process 6.87E-06 0.000602 
GO:0030334 regulation of cell migration 8.34E-06 0.000724 
GO:0030195 negative regulation of blood coagulation 8.69E-06 0.000739 
GO:1900047 negative regulation of hemostasis 8.69E-06 0.000739 
GO:0009636 response to toxic substance 9.20E-06 0.000774 
GO:0098602 single organism cell adhesion 1.09E-05 0.000907 
GO:0097190 apoptotic signaling pathway 1.24E-05 0.001025 
GO:0090330 regulation of platelet aggregation 1.35E-05 0.001096 
GO:0007155 cell adhesion 1.35E-05 0.001096 
GO:0050819 negative regulation of coagulation 1.45E-05 0.00115 
GO:0090303 positive regulation of wound healing 1.45E-05 0.00115 
GO:0009119 ribonucleoside metabolic process 1.55E-05 0.001216 
GO:0051129 negative regulation of cellular component organization 1.60E-05 0.001247 
GO:0022610 biological adhesion 1.63E-05 0.001256 
GO:0009108 coenzyme biosynthetic process 1.85E-05 0.001412 
GO:0040012 regulation of locomotion 1.88E-05 0.001425 
GO:1901657 glycosyl compound metabolic process 1.91E-05 0.001436 
GO:1903035 negative regulation of response to wounding 1.95E-05 0.001447 
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GO:0030036 actin cytoskeleton organization 2.02E-05 0.001481 
GO:0048821 erythrocyte development 2.03E-05 0.001481 
GO:0016477 cell migration 2.09E-05 0.001507 
GO:0008610 lipid biosynthetic process 2.10E-05 0.001507 
GO:0043933 macromolecular complex subunit organization 2.17E-05 0.001543 
GO:0002262 myeloid cell homeostasis 2.27E-05 0.0016 
GO:0044283 small molecule biosynthetic process 2.33E-05 0.001631 
GO:2000145 regulation of cell motility 2.50E-05 0.001734 
GO:2000377 regulation of reactive oxygen species metabolic process 2.79E-05 0.00192 
GO:0040011 locomotion 2.82E-05 0.001926 
GO:0009167 purine ribonucleoside monophosphate metabolic process 2.98E-05 0.002009 
GO:0006915 apoptotic process 3.02E-05 0.002009 
GO:0009116 nucleoside metabolic process 3.03E-05 0.002009 
GO:0044802 single-organism membrane organization 3.07E-05 0.002009 
GO:0007005 mitochondrion organization 3.09E-05 0.002009 
GO:0006811 ion transport 3.09E-05 0.002009 
GO:0009126 purine nucleoside monophosphate metabolic process 3.14E-05 0.002014 
GO:0034599 cellular response to oxidative stress 3.14E-05 0.002014 
GO:2001233 regulation of apoptotic signaling pathway 3.21E-05 0.002038 
GO:0030099 myeloid cell differentiation 3.29E-05 0.002077 
GO:0030335 positive regulation of cell migration 3.33E-05 0.002087 
GO:0044712 single-organism catabolic process 3.37E-05 0.002093 
GO:0031532 actin cytoskeleton reorganization 3.55E-05 0.002193 
GO:1903036 positive regulation of response to wounding 3.58E-05 0.002194 
GO:1901700 response to oxygen-containing compound 3.63E-05 0.00221 
GO:0008219 cell death 3.67E-05 0.002213 
GO:1902533 positive regulation of intracellular signal transduction 3.95E-05 0.002364 
GO:0006638 neutral lipid metabolic process 4.01E-05 0.002364 
GO:0030218 erythrocyte differentiation 4.01E-05 0.002364 
GO:2000021 regulation of ion homeostasis 4.03E-05 0.002364 
GO:0055082 cellular chemical homeostasis 4.32E-05 0.002518 
GO:0019693 ribose phosphate metabolic process 4.39E-05 0.002537 
GO:0012501 programmed cell death 4.52E-05 0.002597 
GO:0009205 purine ribonucleoside triphosphate metabolic process 4.87E-05 0.00278 
GO:0048534 hematopoietic or lymphoid organ development 5.03E-05 0.002849 
GO:0048870 cell motility 5.32E-05 0.002977 
GO:0051674 localization of cell 5.32E-05 0.002977 
GO:0071705 nitrogen compound transport 5.40E-05 0.002998 
GO:0009161 ribonucleoside monophosphate metabolic process 5.47E-05 0.003009 
GO:0080134 regulation of response to stress 5.49E-05 0.003009 
GO:0030029 actin filament-based process 5.55E-05 0.003021 
GO:0009150 purine ribonucleotide metabolic process 5.64E-05 0.003052 
GO:2000147 positive regulation of cell motility 5.84E-05 0.003137 
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GO:0006801 superoxide metabolic process 6.09E-05 0.003252 
GO:0006518 peptide metabolic process 6.59E-05 0.003437 
GO:0006732 coenzyme metabolic process 6.65E-05 0.003437 
GO:0009199 ribonucleoside triphosphate metabolic process 6.66E-05 0.003437 
GO:0035384 thioester biosynthetic process 6.68E-05 0.003437 
GO:0046688 response to copper ion 6.68E-05 0.003437 
GO:0071616 acyl-CoA biosynthetic process 6.68E-05 0.003437 
GO:0010572 positive regulation of platelet activation 6.99E-05 0.003561 
GO:0009144 purine nucleoside triphosphate metabolic process 7.01E-05 0.003561 
GO:0009617 response to bacterium 7.24E-05 0.003654 
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway 7.32E-05 0.003675 
GO:0006637 acyl-CoA metabolic process 7.44E-05 0.003689 
GO:0035383 thioester metabolic process 7.44E-05 0.003689 
GO:0046034 ATP metabolic process 7.53E-05 0.00371 
GO:0051272 positive regulation of cellular component movement 8.04E-05 0.003942 
GO:0006163 purine nucleotide metabolic process 8.21E-05 0.003999 
GO:0019755 one-carbon compound transport 8.61E-05 0.004147 
GO:0016125 sterol metabolic process 8.66E-05 0.004147 
GO:0034101 erythrocyte homeostasis 8.66E-05 0.004147 
GO:0009259 ribonucleotide metabolic process 9.07E-05 0.004317 
GO:0044087 regulation of cellular component biogenesis 9.34E-05 0.004407 
GO:0055085 transmembrane transport 9.36E-05 0.004407 
GO:0098609 cell-cell adhesion 9.45E-05 0.004424 
GO:0033013 tetrapyrrole metabolic process 9.61E-05 0.004475 
GO:0015914 phospholipid transport 9.88E-05 0.004572 
GO:0009123 nucleoside monophosphate metabolic process 0.000101 0.004626 
GO:0033119 negative regulation of RNA splicing 0.000102 0.004654 
GO:0034110 regulation of homotypic cell-cell adhesion 0.000102 0.004654 
GO:0055072 iron ion homeostasis 0.00011 0.004962 
GO:0051270 regulation of cellular component movement 0.000111 0.004976 
GO:0051707 response to other organism 0.000116 0.005191 
GO:0006120 mitochondrial electron transport, NADH to ubiquinone 0.000119 0.005286 
GO:0033993 response to lipid 0.000121 0.005357 
GO:0043207 response to external biotic stimulus 0.000122 0.005357 
GO:0006767 water-soluble vitamin metabolic process 0.000125 0.005462 
GO:1901698 response to nitrogen compound 0.000127 0.005533 
GO:0002520 immune system development 0.000131 0.005685 
GO:0034446 substrate adhesion-dependent cell spreading 0.000132 0.005688 
GO:0030258 lipid modification 0.000134 0.005738 
GO:0010941 regulation of cell death 0.000134 0.005738 
GO:0048585 negative regulation of response to stimulus 0.000136 0.005763 
GO:0040017 positive regulation of locomotion 0.000143 0.006036 
GO:0098771 inorganic ion homeostasis 0.000143 0.006036 
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GO:2000379 positive regulation of reactive oxygen species metabolic process 0.000144 0.006036 
GO:0046686 response to cadmium ion 0.000147 0.006132 
GO:0001894 tissue homeostasis 0.000148 0.00614 
GO:0006650 glycerophospholipid metabolic process 0.000164 0.006744 
GO:0061024 membrane organization 0.000169 0.006935 
GO:0042981 regulation of apoptotic process 0.000172 0.007045 
GO:0043066 negative regulation of apoptotic process 0.000179 0.007268 
GO:0001570 vasculogenesis 0.000187 0.007534 
GO:0034332 adherens junction organization 0.000187 0.007534 
GO:0006639 acylglycerol metabolic process 0.000189 0.007534 
GO:0044272 sulfur compound biosynthetic process 0.000189 0.007534 
GO:0009141 nucleoside triphosphate metabolic process 0.00019 0.007544 
GO:0060548 negative regulation of cell death 0.000205 0.008089 
GO:0043067 regulation of programmed cell death 0.000208 0.008171 
GO:0072224 metanephric glomerulus development 0.000209 0.008171 
GO:0061515 myeloid cell development 0.00021 0.008171 
GO:0006692 prostanoid metabolic process 0.000214 0.008232 
GO:0006693 prostaglandin metabolic process 0.000214 0.008232 
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading 0.000214 0.008232 
GO:0030097 hemopoiesis 0.000221 0.008429 
GO:0043069 negative regulation of programmed cell death 0.000227 0.008654 
GO:0045454 cell redox homeostasis 0.000232 0.008778 
GO:0015670 carbon dioxide transport 0.000238 0.008832 
GO:0018158 protein oxidation 0.000238 0.008832 
GO:0071971 extracellular exosome assembly 0.000238 0.008832 
GO:2001046 positive regulation of integrin-mediated signaling pathway 0.000238 0.008832 
GO:0055080 cation homeostasis 0.000239 0.008832 
GO:1902589 single-organism organelle organization 0.000251 0.009265 
GO:0050686 negative regulation of mRNA processing 0.000253 0.009294 
GO:0006641 triglyceride metabolic process 0.000282 0.010321 
GO:0008203 cholesterol metabolic process 0.000289 0.0105 
GO:0034220 ion transmembrane transport 0.00029 0.010502 
GO:0009607 response to biotic stimulus 0.0003 0.010801 
GO:0034330 cell junction organization 0.000328 0.011771 
GO:0071621 granulocyte chemotaxis 0.00033 0.011805 
GO:0032102 negative regulation of response to external stimulus 0.000332 0.011807 
GO:0015669 gas transport 0.000341 0.012094 
GO:0006084 acetyl-CoA metabolic process 0.000347 0.01223 
GO:0030155 regulation of cell adhesion 0.000348 0.01223 
GO:0043320 natural killer cell degranulation 0.000375 0.013072 
GO:0072239 metanephric glomerulus vasculature development 0.000375 0.013072 
GO:0048008 platelet-derived growth factor receptor signaling pathway 0.000392 0.013593 
GO:0034333 adherens junction assembly 0.000405 0.013973 
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GO:0050790 regulation of catalytic activity 0.000406 0.013973 
GO:0006644 phospholipid metabolic process 0.00041 0.014055 
GO:0051130 positive regulation of cellular component organization 0.000414 0.014147 
GO:0060249 anatomical structure homeostasis 0.000425 0.014412 
GO:0006085 acetyl-CoA biosynthetic process 0.000426 0.014412 
GO:1902652 secondary alcohol metabolic process 0.000428 0.014444 
GO:0044089 positive regulation of cellular component biogenesis 0.000447 0.015019 
GO:0055076 transition metal ion homeostasis 0.000456 0.015263 
GO:0051049 regulation of transport 0.000458 0.015279 
GO:0019220 regulation of phosphate metabolic process 0.000461 0.015285 
GO:0006869 lipid transport 0.000471 0.01557 
GO:0015711 organic anion transport 0.000476 0.01569 
GO:0015748 organophosphate ester transport 0.000482 0.015798 
GO:0010647 positive regulation of cell communication 0.000489 0.01598 
GO:0030595 leukocyte chemotaxis 0.000491 0.015983 
GO:0051174 regulation of phosphorus metabolic process 0.000496 0.016076 
GO:0097734 extracellular exosome biogenesis 0.000524 0.016916 
GO:0046456 icosanoid biosynthetic process 0.000533 0.01701 
GO:0060325 face morphogenesis 0.000533 0.01701 
GO:1901570 fatty acid derivative biosynthetic process 0.000533 0.01701 
GO:0048514 blood vessel morphogenesis 0.000539 0.017137 
GO:0055065 metal ion homeostasis 0.000546 0.017283 
GO:0046113 nucleobase catabolic process 0.000554 0.017385 
GO:0060586 multicellular organismal iron ion homeostasis 0.000554 0.017385 
GO:0007568 aging 0.000555 0.017385 
GO:0023056 positive regulation of signaling 0.000562 0.017521 
GO:0006935 chemotaxis 0.000568 0.017668 
GO:0046903 secretion 0.000581 0.017991 
GO:0042330 taxis 0.000599 0.018424 
GO:0002682 regulation of immune system process 0.000599 0.018424 
GO:0006873 cellular ion homeostasis 0.000604 0.018502 
GO:0051240 positive regulation of multicellular organismal process 0.000624 0.019042 
GO:0045216 cell-cell junction organization 0.000626 0.019042 
GO:0048025 negative regulation of mRNA splicing, via spliceosome 0.000637 0.019307 
GO:0033043 regulation of organelle organization 0.000661 0.01988 
GO:0070509 calcium ion import 0.000661 0.01988 
GO:0016310 phosphorylation 0.000669 0.020049 
GO:0045785 positive regulation of cell adhesion 0.000682 0.020354 
GO:1903312 negative regulation of mRNA metabolic process 0.000693 0.020627 
GO:0090066 regulation of anatomical structure size 0.000709 0.021027 
GO:0032989 cellular component morphogenesis 0.000714 0.021095 
GO:0051881 regulation of mitochondrial membrane potential 0.000726 0.02137 
GO:0010876 lipid localization 0.000751 0.02204 
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GO:0008202 steroid metabolic process 0.000757 0.022125 
GO:0001516 prostaglandin biosynthetic process 0.000767 0.022141 
GO:0019430 removal of superoxide radicals 0.000767 0.022141 
GO:0046457 prostanoid biosynthetic process 0.000767 0.022141 
GO:0045184 establishment of protein localization 0.000768 0.022141 
GO:0097530 granulocyte migration 0.000773 0.022213 
GO:0090331 negative regulation of platelet aggregation 0.000781 0.022249 
GO:0051017 actin filament bundle assembly 0.000782 0.022249 
GO:0006672 ceramide metabolic process 0.000782 0.022249 
GO:0003254 regulation of membrane depolarization 0.000786 0.022266 
GO:0009967 positive regulation of signal transduction 0.000821 0.023195 
GO:0044242 cellular lipid catabolic process 0.000828 0.023304 
GO:0051050 positive regulation of transport 0.000857 0.024017 
GO:0032844 regulation of homeostatic process 0.00086 0.024017 
GO:1901566 organonitrogen compound biosynthetic process 0.000862 0.024017 
GO:0010171 body morphogenesis 0.000876 0.02433 
GO:0050900 leukocyte migration 0.000895 0.024783 
GO:0042554 superoxide anion generation 0.000915 0.025146 
GO:0090322 regulation of superoxide metabolic process 0.000915 0.025146 
GO:0061572 actin filament bundle organization 0.000925 0.025342 
GO:0032956 regulation of actin cytoskeleton organization 0.000995 0.027172 
GO:0072210 metanephric nephron development 0.000998 0.027172 
GO:0042180 cellular ketone metabolic process 0.001039 0.028074 
GO:0044093 positive regulation of molecular function 0.001045 0.028074 
GO:0060191 regulation of lipase activity 0.001049 0.028074 
GO:1903409 reactive oxygen species biosynthetic process 0.001054 0.028074 
GO:0006105 succinate metabolic process 0.001058 0.028074 
GO:0010310 regulation of hydrogen peroxide metabolic process 0.001058 0.028074 
GO:0072488 ammonium transmembrane transport 0.001058 0.028074 
GO:2001044 regulation of integrin-mediated signaling pathway 0.001058 0.028074 
GO:0044270 cellular nitrogen compound catabolic process 0.001066 0.028206 
GO:0071450 cellular response to oxygen radical 0.001081 0.028406 
GO:0071451 cellular response to superoxide 0.001081 0.028406 
GO:0022407 regulation of cell-cell adhesion 0.001094 0.028669 
GO:0046700 heterocycle catabolic process 0.001104 0.028827 
GO:1900024 regulation of substrate adhesion-dependent cell spreading 0.001119 0.029128 
GO:0007045 cell-substrate adherens junction assembly 0.001145 0.029612 
GO:0048041 focal adhesion assembly 0.001145 0.029612 
GO:0006633 fatty acid biosynthetic process 0.001148 0.029612 
GO:0031667 response to nutrient levels 0.001156 0.029721 
GO:1901361 organic cyclic compound catabolic process 0.001184 0.030363 
GO:0043623 cellular protein complex assembly 0.001219 0.031151 
GO:0000302 response to reactive oxygen species 0.001229 0.031321 
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GO:0031401 positive regulation of protein modification process 0.001246 0.031635 
GO:0060323 head morphogenesis 0.00125 0.031656 
GO:0033014 tetrapyrrole biosynthetic process 0.001267 0.031993 
GO:0042063 gliogenesis 0.001278 0.032173 
GO:0006928 movement of cell or subcellular component 0.00132 0.033134 
GO:0043281 regulation of cysteine-type endopeptidase activity involved in 
apoptotic process 
0.001337 0.033459 
GO:0051592 response to calcium ion 0.001349 0.033657 
GO:0032543 mitochondrial translation 0.001356 0.033734 
GO:0010562 positive regulation of phosphorus metabolic process 0.001386 0.033921 
GO:0045937 positive regulation of phosphate metabolic process 0.001386 0.033921 
GO:0006750 glutathione biosynthetic process 0.001391 0.033921 
GO:0015697 quaternary ammonium group transport 0.001391 0.033921 
GO:0033700 phospholipid efflux 0.001391 0.033921 
GO:0042762 regulation of sulfur metabolic process 0.001391 0.033921 
GO:0034113 heterotypic cell-cell adhesion 0.001392 0.033921 
GO:0014070 response to organic cyclic compound 0.001409 0.034233 
GO:0010639 negative regulation of organelle organization 0.001422 0.034435 
GO:0050921 positive regulation of chemotaxis 0.00143 0.034435 
GO:0071456 cellular response to hypoxia 0.00143 0.034435 
GO:0097191 extrinsic apoptotic signaling pathway 0.001461 0.035088 
GO:0006887 exocytosis 0.001492 0.035713 
GO:0060326 cell chemotaxis 0.001518 0.036227 
GO:0019439 aromatic compound catabolic process 0.001541 0.0366 
GO:0009112 nucleobase metabolic process 0.001546 0.0366 
GO:0030834 regulation of actin filament depolymerization 0.001546 0.0366 
GO:0032368 regulation of lipid transport 0.001595 0.037575 
GO:0009064 glutamine family amino acid metabolic process 0.001597 0.037575 
GO:0015850 organic hydroxy compound transport 0.001642 0.038533 
GO:0006952 defense response 0.001652 0.038653 
GO:0043648 dicarboxylic acid metabolic process 0.001703 0.039466 
GO:0090279 regulation of calcium ion import 0.001703 0.039466 
GO:0000303 response to superoxide 0.001705 0.039466 
GO:0006144 purine nucleobase metabolic process 0.001705 0.039466 
GO:0016074 snoRNA metabolic process 0.001782 0.041011 
GO:0050665 hydrogen peroxide biosynthetic process 0.001782 0.041011 
GO:0051247 positive regulation of protein metabolic process 0.00185 0.042453 
GO:0022603 regulation of anatomical structure morphogenesis 0.001865 0.042516 
GO:0019217 regulation of fatty acid metabolic process 0.001868 0.042516 
GO:0030301 cholesterol transport 0.001868 0.042516 
GO:0072523 purine-containing compound catabolic process 0.001891 0.042524 
GO:1905268 negative regulation of chromatin organization 0.001891 0.042524 
GO:0006665 sphingolipid metabolic process 0.001894 0.042524 
GO:0036294 cellular response to decreased oxygen levels 0.001894 0.042524 
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GO:0043901 negative regulation of multi-organism process 0.001894 0.042524 
GO:0032940 secretion by cell 0.001925 0.043103 
GO:0016192 vesicle-mediated transport 0.001953 0.043622 
GO:0006536 glutamate metabolic process 0.00196 0.043651 
GO:0015918 sterol transport 0.002016 0.044783 
GO:0001568 blood vessel development 0.002025 0.04487 
GO:0000902 cell morphogenesis 0.002032 0.044893 
GO:0050920 regulation of chemotaxis 0.002047 0.045068 
GO:0010959 regulation of metal ion transport 0.00205 0.045068 
GO:0044723 single-organism carbohydrate metabolic process 0.002066 0.04529 
GO:0009888 tissue development 0.002079 0.045437 
GO:0006636 unsaturated fatty acid biosynthetic process 0.002083 0.045437 
GO:0051493 regulation of cytoskeleton organization 0.002166 0.046689 
GO:0033554 cellular response to stress 0.002171 0.046689 
GO:0007044 cell-substrate junction assembly 0.002172 0.046689 
GO:0043254 regulation of protein complex assembly 0.002173 0.046689 
GO:0006909 phagocytosis 0.002191 0.046689 
GO:0097529 myeloid leukocyte migration 0.002191 0.046689 
GO:0046165 alcohol biosynthetic process 0.002193 0.046689 
GO:0006520 cellular amino acid metabolic process 0.00221 0.046689 
GO:0002523 leukocyte migration involved in inflammatory response 0.002236 0.046689 
GO:0010544 negative regulation of platelet activation 0.002236 0.046689 
GO:0019184 nonribosomal peptide biosynthetic process 0.002236 0.046689 
GO:0020027 hemoglobin metabolic process 0.002236 0.046689 
GO:0032928 regulation of superoxide anion generation 0.002236 0.046689 
GO:0034111 negative regulation of homotypic cell-cell adhesion 0.002236 0.046689 
GO:0044241 lipid digestion 0.002236 0.046689 
GO:0060192 negative regulation of lipase activity 0.002236 0.046689 
GO:0001819 positive regulation of cytokine production 0.002236 0.046689 
GO:0030042 actin filament depolymerization 0.002289 0.047679 
GO:0097164 ammonium ion metabolic process 0.002295 0.047679 
GO:0034440 lipid oxidation 0.002331 0.048309 
GO:0030003 cellular cation homeostasis 0.002362 0.048837 
GO:0006820 anion transport 0.002419 0.049887 
Table A6. List of Gene Ontology Biological Process redundant terms for e9.5 exclusive DEPs 
geneset description PValue FDR 
GO:0006412 translation 0 0 
GO:0006518 peptide metabolic process 0 0 
GO:0043043 peptide biosynthetic process 0 0 
GO:0043603 cellular amide metabolic process 0 0 
GO:0043604 amide biosynthetic process 0 0 
GO:0043933 macromolecular complex subunit organization 0 0 
GO:1901566 organonitrogen compound biosynthetic process 0 0 
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GO:0007049 cell cycle 1.11E-16 1.16E-13 
GO:0006417 regulation of translation 2.22E-16 1.85E-13 
GO:0034622 cellular macromolecular complex assembly 2.22E-16 1.85E-13 
GO:0044265 cellular macromolecule catabolic process 4.44E-16 3.36E-13 
GO:0034248 regulation of cellular amide metabolic process 8.88E-16 6.17E-13 
GO:0010608 posttranscriptional regulation of gene expression 3.11E-15 1.99E-12 
GO:0006511 ubiquitin-dependent protein catabolic process 7.77E-15 4.62E-12 
GO:0046907 intracellular transport 1.23E-14 6.84E-12 
GO:0033554 cellular response to stress 1.33E-14 6.94E-12 
GO:0019941 modification-dependent protein catabolic process 1.80E-14 8.74E-12 
GO:0006974 cellular response to DNA damage stimulus 1.89E-14 8.74E-12 
GO:0009057 macromolecule catabolic process 2.26E-14 9.93E-12 
GO:0043632 modification-dependent macromolecule catabolic process 3.75E-14 1.56E-11 
GO:0006259 DNA metabolic process 8.42E-14 3.34E-11 
GO:1901564 organonitrogen compound metabolic process 1.28E-13 4.86E-11 
GO:0051649 establishment of localization in cell 1.47E-13 5.31E-11 
GO:0006325 chromatin organization 2.00E-13 6.95E-11 
GO:0022618 ribonucleoprotein complex assembly 2.38E-13 7.93E-11 
GO:0070647 protein modification by small protein conjugation or removal 2.62E-13 8.40E-11 
GO:0016569 covalent chromatin modification 4.70E-13 1.45E-10 
GO:0034613 cellular protein localization 4.88E-13 1.45E-10 
GO:0070727 cellular macromolecule localization 8.68E-13 2.49E-10 
GO:0071826 ribonucleoprotein complex subunit organization 1.27E-12 3.53E-10 
GO:0022613 ribonucleoprotein complex biogenesis 2.20E-12 5.91E-10 
GO:0006886 intracellular protein transport 4.67E-12 1.22E-09 
GO:0006281 DNA repair 4.97E-12 1.23E-09 
GO:0006413 translational initiation 5.02E-12 1.23E-09 
GO:0051603 proteolysis involved in cellular protein catabolic process 6.78E-12 1.61E-09 
GO:0022402 cell cycle process 6.96E-12 1.61E-09 
GO:0000278 mitotic cell cycle 1.11E-11 2.49E-09 
GO:0032446 protein modification by small protein conjugation 2.30E-11 5.04E-09 
GO:1903047 mitotic cell cycle process 2.83E-11 6.04E-09 
GO:0065003 macromolecular complex assembly 3.45E-11 7.18E-09 
GO:0044257 cellular protein catabolic process 6.20E-11 1.26E-08 
GO:0002181 cytoplasmic translation 9.95E-11 1.97E-08 
GO:0044248 cellular catabolic process 1.35E-10 2.61E-08 
GO:0015031 protein transport 2.06E-10 3.91E-08 
GO:0045184 establishment of protein localization 2.39E-10 4.42E-08 
GO:1901575 organic substance catabolic process 2.59E-10 4.70E-08 
GO:0016192 vesicle-mediated transport 4.89E-10 8.66E-08 
GO:0016567 protein ubiquitination 5.16E-10 8.85E-08 
GO:0016570 histone modification 5.20E-10 8.85E-08 
GO:0009056 catabolic process 6.65E-10 1.11E-07 
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GO:0030163 protein catabolic process 7.55E-10 1.23E-07 
GO:0050790 regulation of catalytic activity 1.39E-08 2.22E-06 
GO:0042255 ribosome assembly 1.86E-08 2.93E-06 
GO:0006260 DNA replication 2.40E-08 3.64E-06 
GO:0048193 Golgi vesicle transport 2.40E-08 3.64E-06 
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process 2.85E-08 4.24E-06 
GO:0051276 chromosome organization 4.09E-08 5.98E-06 
GO:0043248 proteasome assembly 5.41E-08 7.78E-06 
GO:0018193 peptidyl-amino acid modification 1.27E-07 1.78E-05 
GO:0010498 proteasomal protein catabolic process 1.28E-07 1.78E-05 
GO:0071103 DNA conformation change 1.35E-07 1.85E-05 
GO:0006396 RNA processing 1.44E-07 1.91E-05 
GO:0007067 mitotic nuclear division 1.44E-07 1.91E-05 
GO:0000280 nuclear division 1.62E-07 2.11E-05 
GO:0002183 cytoplasmic translational initiation 1.89E-07 2.43E-05 
GO:0051726 regulation of cell cycle 2.26E-07 2.85E-05 
GO:0048285 organelle fission 2.48E-07 3.09E-05 
GO:0006261 DNA-dependent DNA replication 3.60E-07 4.41E-05 
GO:0044093 positive regulation of molecular function 3.78E-07 4.57E-05 
GO:0033043 regulation of organelle organization 4.79E-07 5.69E-05 
GO:0033522 histone H2A ubiquitination 5.46E-07 6.40E-05 
GO:0042254 ribosome biogenesis 7.60E-07 8.79E-05 
GO:1902580 single-organism cellular localization 9.03E-07 0.000103 
GO:0051301 cell division 9.34E-07 0.000105 
GO:1902589 single-organism organelle organization 1.02E-06 0.000114 
GO:0006270 DNA replication initiation 1.09E-06 0.000119 
GO:0048468 cell development 1.86E-06 0.000201 
GO:0032259 methylation 1.88E-06 0.000201 
GO:0006913 nucleocytoplasmic transport 1.97E-06 0.000208 
GO:0000209 protein polyubiquitination 2.07E-06 0.000215 
GO:0042147 retrograde transport, endosome to Golgi 2.15E-06 0.000219 
GO:0071353 cellular response to interleukin-4 2.16E-06 0.000219 
GO:0051169 nuclear transport 2.39E-06 0.000239 
GO:0043085 positive regulation of catalytic activity 2.54E-06 0.000252 
GO:0051052 regulation of DNA metabolic process 3.09E-06 0.000301 
GO:0016482 cytosolic transport 3.10E-06 0.000301 
GO:0034660 ncRNA metabolic process 3.93E-06 0.000376 
GO:0006605 protein targeting 4.02E-06 0.00038 
GO:0051172 negative regulation of nitrogen compound metabolic process 4.20E-06 0.000394 
GO:0043414 macromolecule methylation 4.42E-06 0.000409 
GO:0009411 response to UV 5.02E-06 0.00046 
GO:0006890 retrograde vesicle-mediated transport, Golgi to ER 5.38E-06 0.000482 
GO:0070670 response to interleukin-4 5.38E-06 0.000482 
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GO:0007010 cytoskeleton organization 5.47E-06 0.000485 
GO:0080135 regulation of cellular response to stress 5.63E-06 0.000494 
GO:0009314 response to radiation 5.91E-06 0.000513 
GO:0031365 N-terminal protein amino acid modification 6.21E-06 0.000533 
GO:0098609 cell-cell adhesion 7.24E-06 0.000616 
GO:0033365 protein localization to organelle 7.47E-06 0.000629 
GO:2001020 regulation of response to DNA damage stimulus 8.01E-06 0.000667 
GO:0018205 peptidyl-lysine modification 8.10E-06 0.000668 
GO:0018210 peptidyl-threonine modification 8.69E-06 0.00071 
GO:0072594 establishment of protein localization to organelle 9.43E-06 0.000759 
GO:0006401 RNA catabolic process 9.48E-06 0.000759 
GO:0071495 cellular response to endogenous stimulus 1.30E-05 0.001033 
GO:0070925 organelle assembly 1.34E-05 0.001056 
GO:0006333 chromatin assembly or disassembly 1.42E-05 0.001104 
GO:0034470 ncRNA processing 1.45E-05 0.001121 
GO:0001701 in utero embryonic development 1.54E-05 0.001176 
GO:0019081 viral translation 1.56E-05 0.00118 
GO:0075525 viral translational termination-reinitiation 1.62E-05 0.001214 
GO:0016571 histone methylation 1.77E-05 0.001316 
GO:0032269 negative regulation of cellular protein metabolic process 2.01E-05 0.001484 
GO:0007346 regulation of mitotic cell cycle 2.09E-05 0.00153 
GO:0006474 N-terminal protein amino acid acetylation 2.18E-05 0.001581 
GO:0018107 peptidyl-threonine phosphorylation 2.25E-05 0.001615 
GO:0031396 regulation of protein ubiquitination 2.40E-05 0.00171 
GO:0018209 peptidyl-serine modification 2.43E-05 0.001713 
GO:0043623 cellular protein complex assembly 2.48E-05 0.001734 
GO:0007155 cell adhesion 2.52E-05 0.001751 
GO:0051170 nuclear import 2.69E-05 0.001834 
GO:0010564 regulation of cell cycle process 2.70E-05 0.001834 
GO:0017148 negative regulation of translation 2.71E-05 0.001834 
GO:0044770 cell cycle phase transition 2.73E-05 0.001834 
GO:0034655 nucleobase-containing compound catabolic process 2.79E-05 0.001859 
GO:0006268 DNA unwinding involved in DNA replication 3.01E-05 0.001981 
GO:0006479 protein methylation 3.06E-05 0.001981 
GO:0008213 protein alkylation 3.06E-05 0.001981 
GO:0031399 regulation of protein modification process 3.07E-05 0.001981 
GO:0006508 proteolysis 3.10E-05 0.00199 
GO:0006470 protein dephosphorylation 3.22E-05 0.002031 
GO:0000956 nuclear-transcribed mRNA catabolic process 3.22E-05 0.002031 
GO:0022610 biological adhesion 3.27E-05 0.002048 
GO:0006891 intra-Golgi vesicle-mediated transport 3.60E-05 0.002239 
GO:0072359 circulatory system development 3.93E-05 0.002427 
GO:0016071 mRNA metabolic process 3.96E-05 0.002428 
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GO:0018022 peptidyl-lysine methylation 4.05E-05 0.002464 
GO:0006302 double-strand break repair 4.21E-05 0.002539 
GO:0016310 phosphorylation 4.66E-05 0.002748 
GO:0010216 maintenance of DNA methylation 4.69E-05 0.002748 
GO:0075522 IRES-dependent viral translational initiation 4.69E-05 0.002748 
GO:1905214 regulation of RNA binding 4.69E-05 0.002748 
GO:0016574 histone ubiquitination 4.75E-05 0.002748 
GO:2000779 regulation of double-strand break repair 4.75E-05 0.002748 
GO:0006338 chromatin remodeling 4.84E-05 0.002783 
GO:0071310 cellular response to organic substance 4.92E-05 0.002807 
GO:0016579 protein deubiquitination 5.07E-05 0.002854 
GO:0034728 nucleosome organization 5.07E-05 0.002854 
GO:0051568 histone H3-K4 methylation 5.11E-05 0.00286 
GO:0044772 mitotic cell cycle phase transition 5.19E-05 0.002884 
GO:0002192 IRES-dependent translational initiation 5.32E-05 0.002895 
GO:0006335 DNA replication-dependent nucleosome assembly 5.32E-05 0.002895 
GO:0034723 DNA replication-dependent nucleosome organization 5.32E-05 0.002895 
GO:0006323 DNA packaging 5.47E-05 0.002961 
GO:0034968 histone lysine methylation 5.76E-05 0.003097 
GO:0006468 protein phosphorylation 5.84E-05 0.003117 
GO:0051640 organelle localization 5.92E-05 0.003119 
GO:0006606 protein import into nucleus 5.96E-05 0.003119 
GO:0044744 protein targeting to nucleus 5.96E-05 0.003119 
GO:0018105 peptidyl-serine phosphorylation 5.99E-05 0.003119 
GO:0006513 protein monoubiquitination 6.09E-05 0.003152 
GO:1902593 single-organism nuclear import 6.37E-05 0.003276 
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic 
process 
6.49E-05 0.003315 
GO:0006402 mRNA catabolic process 6.58E-05 0.003323 
GO:0017038 protein import 6.61E-05 0.003323 
GO:0034249 negative regulation of cellular amide metabolic process 6.62E-05 0.003323 
GO:0006473 protein acetylation 6.89E-05 0.003438 
GO:0051248 negative regulation of protein metabolic process 6.99E-05 0.003467 
GO:1990090 cellular response to nerve growth factor stimulus 7.40E-05 0.003646 
GO:0010629 negative regulation of gene expression 7.76E-05 0.003805 
GO:0031175 neuron projection development 8.27E-05 0.004027 
GO:0071108 protein K48-linked deubiquitination 8.32E-05 0.004032 
GO:0017015 regulation of transforming growth factor beta receptor signaling 
pathway 
9.18E-05 0.004394 
GO:1903844 regulation of cellular response to transforming growth factor beta 
stimulus 
9.18E-05 0.004394 
GO:1990089 response to nerve growth factor 9.23E-05 0.004394 
GO:0070646 protein modification by small protein removal 9.73E-05 0.004581 
GO:0016055 Wnt signaling pathway 9.73E-05 0.004581 
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GO:0022008 neurogenesis 0.000101 0.004715 
GO:0033962 cytoplasmic mRNA processing body assembly 0.000102 0.004742 
GO:0198738 cell-cell signaling by wnt 0.000102 0.004742 
GO:0006610 ribosomal protein import into nucleus 0.000106 0.004836 
GO:1900044 regulation of protein K63-linked ubiquitination 0.000106 0.004836 
GO:0009792 embryo development ending in birth or egg hatching 0.00011 0.005024 
GO:0006282 regulation of DNA repair 0.000114 0.00514 
GO:0034504 protein localization to nucleus 0.000114 0.00514 
GO:0006446 regulation of translational initiation 0.000117 0.005261 
GO:0071824 protein-DNA complex subunit organization 0.00012 0.005335 
GO:0009719 response to endogenous stimulus 0.000123 0.00547 
GO:0007017 microtubule-based process 0.000126 0.005542 
GO:0008283 cell proliferation 0.000131 0.00576 
GO:1903320 regulation of protein modification by small protein conjugation or 
removal 
0.000134 0.005829 
GO:0010976 positive regulation of neuron projection development 0.000137 0.005947 
GO:1901990 regulation of mitotic cell cycle phase transition 0.000143 0.006191 
GO:0009451 RNA modification 0.000157 0.006751 
GO:0048666 neuron development 0.000159 0.006809 
GO:0043009 chordate embryonic development 0.000169 0.007165 
GO:1905114 cell surface receptor signaling pathway involved in cell-cell signaling 0.00018 0.007596 
GO:0040007 growth 0.000185 0.007773 
GO:0048699 generation of neurons 0.000186 0.007787 
GO:0051129 negative regulation of cellular component organization 0.000195 0.00813 
GO:0030518 intracellular steroid hormone receptor signaling pathway 0.000203 0.008369 
GO:1903960 negative regulation of anion transmembrane transport 0.000204 0.008369 
GO:0016126 sterol biosynthetic process 0.000205 0.008369 
GO:0019080 viral gene expression 0.000205 0.008369 
GO:0002190 cap-independent translational initiation 0.000207 0.008407 
GO:0051345 positive regulation of hydrolase activity 0.000208 0.008426 
GO:0048589 developmental growth 0.000212 0.008522 
GO:0030030 cell projection organization 0.000219 0.008789 
GO:0016197 endosomal transport 0.000248 0.00982 
GO:0043543 protein acylation 0.000248 0.00982 
GO:0031497 chromatin assembly 0.00025 0.009876 
GO:0008219 cell death 0.000256 0.010062 
GO:1902582 single-organism intracellular transport 0.000274 0.010715 
GO:0045595 regulation of cell differentiation 0.000279 0.010855 
GO:0042273 ribosomal large subunit biogenesis 0.000281 0.010902 
GO:0080134 regulation of response to stress 0.000295 0.011361 
GO:0051571 positive regulation of histone H3-K4 methylation 0.000299 0.011441 
GO:0080182 histone H3-K4 trimethylation 0.000299 0.011441 
GO:0044033 multi-organism metabolic process 0.000322 0.012241 
GO:0051865 protein autoubiquitination 0.000327 0.012253 
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GO:0030511 positive regulation of transforming growth factor beta receptor 
signaling pathway 
0.000328 0.012253 
GO:0033260 nuclear DNA replication 0.000328 0.012253 
GO:1903846 positive regulation of cellular response to transforming growth factor 
beta stimulus 
0.000328 0.012253 
GO:0016458 gene silencing 0.000337 0.012544 
GO:0006475 internal protein amino acid acetylation 0.00036 0.013321 
GO:1990778 protein localization to cell periphery 0.000364 0.013433 
GO:0006970 response to osmotic stress 0.000367 0.013467 
GO:0016311 dephosphorylation 0.000373 0.013637 
GO:0000226 microtubule cytoskeleton organization 0.000376 0.013669 
GO:0032392 DNA geometric change 0.000379 0.013741 
GO:0044270 cellular nitrogen compound catabolic process 0.000383 0.013823 
GO:0009790 embryo development 0.000385 0.013843 
GO:0010212 response to ionizing radiation 0.000392 0.014014 
GO:2000113 negative regulation of cellular macromolecule biosynthetic process 0.000397 0.01415 
GO:0046700 heterocycle catabolic process 0.000404 0.01434 
GO:0006400 tRNA modification 0.000417 0.01473 
GO:0016573 histone acetylation 0.000424 0.01491 
GO:0009894 regulation of catabolic process 0.000428 0.014967 
GO:1901987 regulation of cell cycle phase transition 0.000439 0.015308 
GO:0044403 symbiosis, encompassing mutualism through parasitism 0.000449 0.015511 
GO:0044419 interspecies interaction between organisms 0.000449 0.015511 
GO:0007179 transforming growth factor beta receptor signaling pathway 0.000459 0.015789 
GO:0072659 protein localization to plasma membrane 0.000473 0.016157 
GO:0043967 histone H4 acetylation 0.000473 0.016157 
GO:0071822 protein complex subunit organization 0.000487 0.016569 
GO:0010558 negative regulation of macromolecule biosynthetic process 0.000496 0.01677 
GO:0051053 negative regulation of DNA metabolic process 0.000499 0.01677 
GO:0060284 regulation of cell development 0.000501 0.01677 
GO:0012501 programmed cell death 0.000501 0.01677 
GO:0051336 regulation of hydrolase activity 0.000512 0.017062 
GO:0031047 gene silencing by RNA 0.000528 0.017533 
GO:0032270 positive regulation of cellular protein metabolic process 0.000548 0.018118 
GO:0032870 cellular response to hormone stimulus 0.000558 0.018367 
GO:0006271 DNA strand elongation involved in DNA replication 0.000572 0.018618 
GO:0045945 positive regulation of transcription from RNA polymerase III promoter 0.000572 0.018618 
GO:0000028 ribosomal small subunit assembly 0.000574 0.018618 
GO:0006607 NLS-bearing protein import into nucleus 0.000574 0.018618 
GO:0032508 DNA duplex unwinding 0.000579 0.018695 
GO:0071478 cellular response to radiation 0.000583 0.018755 
GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 0.000608 0.019483 
GO:0051130 positive regulation of cellular component organization 0.000613 0.019558 
GO:0018393 internal peptidyl-lysine acetylation 0.000622 0.019769 
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GO:0072358 cardiovascular system development 0.000642 0.020327 
GO:0000075 cell cycle checkpoint 0.000645 0.020357 
GO:0006334 nucleosome assembly 0.000656 0.020546 
GO:0045786 negative regulation of cell cycle 0.000656 0.020546 
GO:0090502 RNA phosphodiester bond hydrolysis, endonucleolytic 0.000661 0.020627 
GO:0019439 aromatic compound catabolic process 0.000681 0.021155 
GO:0007023 post-chaperonin tubulin folding pathway 0.000735 0.022447 
GO:0051138 positive regulation of NK T cell differentiation 0.000735 0.022447 
GO:0070389 chaperone cofactor-dependent protein refolding 0.000735 0.022447 
GO:0070535 histone H2A K63-linked ubiquitination 0.000735 0.022447 
GO:0001944 vasculature development 0.000736 0.022447 
GO:0072657 protein localization to membrane 0.000745 0.022664 
GO:0034724 DNA replication-independent nucleosome organization 0.000767 0.023247 
GO:0031346 positive regulation of cell projection organization 0.00079 0.023771 
GO:0051098 regulation of binding 0.00079 0.023771 
GO:0071407 cellular response to organic cyclic compound 0.000817 0.024478 
GO:0006303 double-strand break repair via nonhomologous end joining 0.000831 0.024808 
GO:0031400 negative regulation of protein modification process 0.000848 0.025228 
GO:0051173 positive regulation of nitrogen compound metabolic process 0.000853 0.025299 
GO:0006284 base-excision repair 0.000864 0.02553 
GO:0006896 Golgi to vacuole transport 0.000868 0.025544 
GO:0060070 canonical Wnt signaling pathway 0.000888 0.02599 
GO:0018394 peptidyl-lysine acetylation 0.000893 0.02599 
GO:0009416 response to light stimulus 0.000894 0.02599 
GO:0016032 viral process 0.000895 0.02599 
GO:1901653 cellular response to peptide 0.000945 0.027326 
GO:0031328 positive regulation of cellular biosynthetic process 0.000967 0.027883 
GO:0031327 negative regulation of cellular biosynthetic process 0.000971 0.027885 
GO:0030182 neuron differentiation 0.000986 0.02822 
GO:0006461 protein complex assembly 0.001005 0.028477 
GO:0006298 mismatch repair 0.001005 0.028477 
GO:0038202 TORC1 signaling 0.001005 0.028477 
GO:0032008 positive regulation of TOR signaling 0.001019 0.02863 
GO:0051569 regulation of histone H3-K4 methylation 0.001019 0.02863 
GO:0018023 peptidyl-lysine trimethylation 0.001021 0.02863 
GO:0070271 protein complex biogenesis 0.00103 0.028737 
GO:0009725 response to hormone 0.001033 0.028737 
GO:0009890 negative regulation of biosynthetic process 0.001037 0.028737 
GO:0006915 apoptotic process 0.001039 0.028737 
GO:0006414 translational elongation 0.001042 0.028737 
GO:0071900 regulation of protein serine/threonine kinase activity 0.001046 0.028757 
GO:0045666 positive regulation of neuron differentiation 0.001057 0.028968 
GO:0001568 blood vessel development 0.001068 0.029171 
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GO:0009891 positive regulation of biosynthetic process 0.001085 0.029502 
GO:0045185 maintenance of protein location 0.001091 0.029502 
GO:0031060 regulation of histone methylation 0.001094 0.029502 
GO:0031397 negative regulation of protein ubiquitination 0.001094 0.029502 
GO:0044764 multi-organism cellular process 0.001107 0.029746 
GO:0051493 regulation of cytoskeleton organization 0.001124 0.030122 
GO:0051099 positive regulation of binding 0.001152 0.030768 
GO:0033059 cellular pigmentation 0.001199 0.031902 
GO:0031329 regulation of cellular catabolic process 0.001217 0.032299 
GO:0045934 negative regulation of nucleobase-containing compound metabolic 
process 
0.001236 0.032628 
GO:0065004 protein-DNA complex assembly 0.001238 0.032628 
GO:0001731 formation of translation preinitiation complex 0.001258 0.032948 
GO:0035518 histone H2A monoubiquitination 0.001258 0.032948 
GO:0010256 endomembrane system organization 0.001301 0.033906 
GO:0044087 regulation of cellular component biogenesis 0.001302 0.033906 
GO:0006399 tRNA metabolic process 0.001346 0.034928 
GO:0071417 cellular response to organonitrogen compound 0.00137 0.035458 
GO:0034101 erythrocyte homeostasis 0.001404 0.036032 
GO:0000056 ribosomal small subunit export from nucleus 0.001423 0.036032 
GO:0000059 protein import into nucleus, docking 0.001423 0.036032 
GO:0019919 peptidyl-arginine methylation, to asymmetrical-dimethyl arginine 0.001423 0.036032 
GO:0030174 regulation of DNA-dependent DNA replication initiation 0.001423 0.036032 
GO:0051136 regulation of NK T cell differentiation 0.001423 0.036032 
GO:0090160 Golgi to lysosome transport 0.001423 0.036032 
GO:0030324 lung development 0.001429 0.036067 
GO:0043255 regulation of carbohydrate biosynthetic process 0.00145 0.036496 
GO:0031344 regulation of cell projection organization 0.001456 0.036536 
GO:0042992 negative regulation of transcription factor import into nucleus 0.001494 0.037258 
GO:0071364 cellular response to epidermal growth factor stimulus 0.001494 0.037258 
GO:0007093 mitotic cell cycle checkpoint 0.001512 0.0376 
GO:0051247 positive regulation of protein metabolic process 0.001535 0.038067 
GO:0042274 ribosomal small subunit biogenesis 0.00155 0.038329 
GO:1901699 cellular response to nitrogen compound 0.001555 0.038329 
GO:0006892 post-Golgi vesicle-mediated transport 0.001613 0.039516 
GO:0032507 maintenance of protein location in cell 0.001613 0.039516 
GO:0010907 positive regulation of glucose metabolic process 0.001627 0.03974 
GO:0030323 respiratory tube development 0.00169 0.041168 
GO:0016050 vesicle organization 0.001705 0.04141 
GO:0044092 negative regulation of molecular function 0.00171 0.04141 
GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity 0.001733 0.041717 
GO:1901216 positive regulation of neuron death 0.001733 0.041717 
GO:0043217 myelin maintenance 0.001755 0.042143 
GO:0010557 positive regulation of macromolecule biosynthetic process 0.00182 0.043581 
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GO:0007568 aging 0.001832 0.043731 
GO:0043044 ATP-dependent chromatin remodeling 0.001881 0.044634 
GO:0045806 negative regulation of endocytosis 0.001881 0.044634 
GO:0031647 regulation of protein stability 0.001886 0.044634 
GO:0010975 regulation of neuron projection development 0.001901 0.044869 
GO:1904029 regulation of cyclin-dependent protein kinase activity 0.001931 0.045454 
GO:0071214 cellular response to abiotic stimulus 0.001961 0.046019 
GO:0016358 dendrite development 0.001975 0.046083 
GO:0030522 intracellular receptor signaling pathway 0.001975 0.046083 
GO:0071375 cellular response to peptide hormone stimulus 0.001985 0.046118 
GO:0022411 cellular component disassembly 0.001987 0.046118 
GO:1901701 cellular response to oxygen-containing compound 0.002017 0.046675 
GO:0051338 regulation of transferase activity 0.002034 0.046863 
GO:0007507 heart development 0.002036 0.046863 
GO:1901361 organic cyclic compound catabolic process 0.002086 0.047885 
GO:0044786 cell cycle DNA replication 0.00212 0.048512 
GO:1902275 regulation of chromatin organization 0.002131 0.048645 
GO:0071559 response to transforming growth factor beta 0.002173 0.049334 
GO:0071560 cellular response to transforming growth factor beta stimulus 0.002173 0.049334 
 
